DIFFERENTIAL BIOMARKERS OF ASTHMA (Machine-translation by Google Translate, not legally binding)

专利摘要:
Differential biomarkers of asthma. In the present invention, therefore, the utility of studying the expression of 8 proteins, 5 in serum and 3 by western-blotting (as described in the examples of the invention), as potential differential biomarkers of various clinical phenotypes: Non-Allergic Asthma (ANA), Allergic Asthma (AA) and Allergy without asthma (A), as well as, differential biomarkers of severity in asthma: ANA Severe vs. Moderate/mild ANA (M/l) and Severe AA vs AA Moderate/slight (M/l). Likewise, the present invention provides a series of biomarkers capable of discriminating between different clinical phenotypes as illustrated throughout the description. (Machine-translation by Google Translate, not legally binding)
公开号:ES2753602A2
申请号:ES202030118
申请日:2017-07-19
公开日:2020-04-13
发明作者:Olombrada Blanca Cárdaba；Muñiz Selene Baos；Ricote David Calzada；Jimeno Lucía Cremades
申请人:Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz；
IPC主号:

专利说明:

[0001] Differential biomarkers of asthma
[0002] Field of technique
[0003]
[0004] The present invention is framed in the medical field, in particular in the field of medical diagnosis using biomarkers capable of discriminating between individuals with different clinical phenotypes of asthma as well as the severity of each of these clinical phenotypes.
[0005]
[0006] Background of the Invention
[0007]
[0008] Chronic inflammatory respiratory diseases, including allergic diseases and asthma, are common, complex and heterogeneous diseases, which is why their clinical evolution and treatment are not always predictable.
[0009]
[0010] Allergic diseases are adverse reactions of the immune system against theoretically innocuous substances whose prevalence, in addition to being very high throughout the world, is increasing, although variably according to lifestyle, reflecting its multifactorial nature. As highlighted by the European Academy of Allergy and Clinical Immunology (EAACI), today, allergy is a public health problem of pandemic proportions, affecting more than 150 million people in Europe; in fact, it is the most common chronic disease. Taking into account epidemiological trends, EAACI estimates that more than half of the European population will suffer from some type of allergy in 2025. This high prevalence and its impact on quality of life make it a serious economic problem (lower productivity of those affected and greater absenteeism from work) and for public health systems. It is estimated that the most common clinical manifestations of this type of disease, asthma and rhinitis, represent more than 100 million days of absenteeism from work or school per year.
[0011]
[0012] Bronchial asthma is an inflammatory disease of the airways that causes bronchial hyperresponsiveness and / or obstruction of air flow characterized by symptoms such as cough, wheezing, or dyspnea. The World Health Organization (WHO) defines it as the most common chronic disease in children and it is estimated that there are more than 300 million affected. Of these, approximately 10% show severe asthma symptoms, with significant morbidity and mortality. In the latest Global Initiative for Asthma (GINA) it was defined as "a heterogeneous disease, usually characterized by chronic inflammation of the airways". It is characterized by a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough that vary in intensity over time. and it is associated with a variable limitation of expiratory air flow. However, one of the main problems in defining this pathology is its wide clinical spectrum, from an occasional episode (which can be easily reversed) to a sustained blockage that requires high doses of oral or inhaled corticosteroids. In the medical community, it is generally accepted that the observed clinical differences in responses to treatment or over the course of disease over time are related to multiple underlying variations in genetic, pharmacological, physiological, biological, and / or immunological that produce subclasses of phenotypes called endotypes. This heterogeneity has led to the call for a search for precision or personalized medicine (among others). For this reason, there are more and more groups talking about endotypes or various forms of the disease, which requires different diagnostic and therapeutic approaches, as has been recently reviewed by experts in this area.
[0013]
[0014] Probably due to this great complexity and heterogeneity, so far, there is no cure for asthma. The main objective of asthma treatment is to achieve and maintain control of the disease as soon as possible, in addition to preventing exacerbations and chronic obstruction to airflow and minimizing mortality. The goals of treatment, both in terms of controlling daily symptoms (current control domain), and to prevent exacerbations and an exaggerated loss of lung function (future risk domain), can be achieved in a high percentage of patients with adequate treatment , but there is always a proportion that does not respond adequately to any treatment.
[0015]
[0016] Multiple studies have characterized various phenotypes of the disease in certain groups of patients with recognizable demographic, clinical, or pathophysiological characteristics. However, although in patients with severe uncontrolled asthma, such a classification may be helpful in guiding specific treatments, at the moment there is no robust evidence to recommend a classification of the disease based on phenotypes of asthma in general, and in which it is control with usual treatment, in particular. Asthma phenotypes can be grouped into three large blocks (not mutually exclusive): clinical or physiological, related to triggers and inflammatory (Table 1).
[0017]
[0018] Table 1. Asthmatic Phenotypes
[0019] Clinical or severe asthma.
[0020] Physiological Asthma with severe exacerbations.
[0021] Asthma refractory to treatment, especially in patients without allergies and corticodependent asthma.
[0022] Asthma of early onset, in children under 12 years, which is usually allergic. Late-onset asthma, especially women, begins in adulthood and usually occurs without allergies.
[0023] Asthma with fixed limitation to air flow, due to bronchial remodeling; due to overlapping asthma syndrome and COPD.
[0024] Asthma and obesity, with severe symptoms.
[0025] Related to allergic asthma, by environmental or occupational allergens. Triggers Asthma induced by non-steroidal anti-inflammatory drugs (NSAIDs).
[0026] Menstruation-induced asthma.
[0027] Exercise-induced asthma.
[0028] Inflammatory Eosinophilic asthma, is usually allergic and has a good response to inhaled glucocorticoids, in general.
[0029] Neutrophilic asthma, usually occurs in patients with severe disease and severe exacerbations, with a worse response to inhaled glucocorticoids.
[0030] Paucigranulocytic asthma.
[0031] Taken from the Spanish Guide for Asthma Management, GEMA 4.0
[0032]
[0033] Classification of adult asthma. Clinical severity. Asthma has been commonly classified according to severity, although the definition has evolved over time. Asthma severity is an intrinsic property of the disease, reflecting the intensity of pathophysiological abnormalities. Keep in mind that the severity of asthma involves both the intensity of the process and the response to treatment. Severity is usually assessed when the patient is being treated and classified based on the maintenance treatment needs that are required to achieve control of symptoms and exacerbations. Traditionally it is divided into four categories: intermittent, mild persistent, moderate persistent, and severe persistent (Table 2).
[0034]
[0035] The severity is not a necessarily constant characteristic of asthma, but can vary over time (in months or years), so it is necessary to reassess it periodically. The severity is determined retrospectively in the patient whose asthma is controlled according to the therapeutic step in which he is, that is, based on the amount of medication that is necessary to maintain control of the disease, resorting to the reduction of the step if it was necessary to stipulate the quantities treatment minimums. It can be established in a patient who is not receiving maintenance treatment, but this is rare.
[0036]
[0037] Control. Asthma control is the degree to which asthma manifestations are absent or minimized by therapeutic interventions and treatment goals are met. Control largely reflects the adequacy of asthma treatment. However, another factor must be taken into account, which differs from one patient to another, and that is the response to treatment and the ease and speed with which control is achieved. Although the term control is broad and can encompass all clinical and pathophysiological aspects of asthma, for practical purposes it includes the clinical characteristics of the disease (symptoms and exacerbations) and pulmonary function tests.
[0038]
[0039] Table 2. Classification of asthma according to severity.
[0040] Intermittent Persistent Mild Persistent Persistent moderate severe Symptoms No More than 2 times Symptoms a Daytime symptoms (2 times or a week daily continuous less than (several times a week) day) Medication of No More than 2 times Every day Several times to relief (agonist (2 times a week or
[0041] 0 ^two -adrenergic less / but not daily
[0042] short-action week)
[0043] Symptoms No more than 2 More than 2 More than once Frequent nocturnal times a month a month a week
[0044] Limitation of None Somewhat Quite a lot of activity
[0045] Function> 80% <80%> 60% - <80% <60% pulmonary (FEV i
[0046] or PEF)% theoretical
[0047] Exacerbations None One or none at Two or more at Two or more a year year year
[0048] Taken from the Spanish Guide for Asthma Management, GEMA 4.0. FEVi: Forced expiratory volume in the first second; PEF: Maximum expiratory flow.
[0049] Drugs to treat asthma are classified as control or maintenance, and relief, also called "rescue." Control or maintenance drugs , which must be administered daily for long periods, include inhaled glucocorticoids (GCI) or systemic, leukotriene receptor antagonists (ARLT), long-acting p2-adrenergic agonists (LABA), tiotropium, and anti-IgE monoclonal antibodies (omalizumab). Chromones and delayed-release theophylline have fallen out of use due to their lower efficacy. Relief medications are used on demand to rapidly treat or prevent bronchoconstriction, and include inhaled short-acting p2-adrenergic agonists (SABAs) (of choice) and inhaled anticholinergics (ipratropium bromide).
[0050]
[0051] Severe asthma is characterized by the need to require multiple drugs at high doses for treatment. It is associated with a higher consumption of economic resources compared to moderate or mild asthma. Uncontrolled severe asthma (AGNC ) is defined as asthmatic disease that persists poorly controlled despite receiving treatment with a combination of GCI / LABA, at high doses in the last year, or oral glucocorticoids for at least six months of the same period. .
[0052]
[0053] Technical problems solved by the present invention
[0054]
[0055] As previously described, from a clinical point of view, asthma is a very heterogeneous disease, with a large number of different phenotypes. However, despite this clinical heterogeneity of asthma, allergic mechanisms have been implicated in 50-80% of asthmatic patients and in approximately 50% of severe asthma. This is one of the reasons why asthma has been commonly associated with respiratory inflammation of type 2 (Th2), characterized by high levels of IgE, eosinophils and some cytokines such as IL4, IL5, IL13 and IL9, canonically associated with Allergic responses and for that reason, a large part of the efforts in the search for new treatments for asthma, have focused on the Th2 cytokine pathway. However, the type 2 immune response is a complex endotype, with several subendotypes, such as endotypes defined as IL-5-high, IL-13-high or IgE-high that define patient subgroups that would have therapeutic benefits with different treatment targets. New strategies have been used for the discovery and validation of molecular biomarkers as omic approaches to reveal the mechanisms responsible for asthma endotypes in different tissues. A biomarker is defined as a measurable, objective parameter that can be the signature of a complex underlying pathway or a key molecule associated with, or that directly plays an essential role in an endotype of a particular disease. Several new experimental treatments, known as biological therapies, are at various stages of clinical development for patients with inflammation driven by a type 2 immune response: anti-IL-4 antibodies. / IL-13, anti-IL-4, anti-IL-5 and anti-IgE, as well as CRTH2 (homologous chemokine receptor of a molecule expressed in Th2 lymphocytes). A summary of the status of these biological therapies today is outlined in Tables 3 and 4. However, currently, the available biomarkers are not specific enough to select the specifically responsive type 2 immune response asthma subendotype. to targeted treatment. This may be due to various factors, such as genetic (or epigenetic) influence or ignorance of the predominant immune inflammatory pathway or contribution to the response of the remodeled tissue itself. In summary, although recent therapeutic advances have unraveled some of the contributions of different phenotypes and endotypes to the pathogenesis of asthma and responses to specific therapies, more information is still needed to optimize the patient's therapeutic responses, trying to avoid the same time adverse effects.
[0056] Table 3. Asthma Treatments with Biomarker Driven Approaches
[0057] Biomarker Treatment with Associations Comments (points to be taken into account, produce variability / fluctuation) response
[0058] Blood
[0059] Eosinophils Anti-IL-5 Exacerbations Easily available
[0060] Anti-IgE Reduction of FP Significant fluctuation Anti-IL-4 / IL-13 Fixed obstruction of
[0061] Corticosteroid pathways
[0062] Respiratory CRTH2 antagonists
[0063] Specific IgE Anti-IgE Exacerbations
[0064] AIT AHR (AIT)
[0065] Periostin Anti-IL-13 Decreased In Research
[0066] DPP-4 FP Test Dependent Exacerbations
[0067] Induced sputum
[0068] Eosinophils Anti-IL-5 Exacerbations Under investigation
[0069] ICS Significant fluctuation
[0070] IL-13 Anti-IL-13 Unknown Under investigation
[0071] Exhaled air
[0072] FENO Anti-IL-5 Exacerbations, Easily available
[0073] Anti-IgE decreased Fluctuation significant Anti-IL-13 FP
[0074] ICS
[0075] Metabolomics ICS Unknown Under investigation
[0076] (VOC)
[0077] There is a significant overlap between the biomarkers used to predict the response to different strategies directed by the endotype. Furthermore, few biomarkers are readily available, most fluctuate significantly, and none are yet validated or quality assured. TIA, allergen immunotherapy; DPP-4, dipeptidyl peptidase 4; ICS, inhaled corticosteroids; FP, lung function; VOC, volatile organic components.
[0078] Table 4. Endotype-Directed Treatments in Th2-type Asthma.
[0079] Biomarker Drug Target Effects Predictive status regulation Eosinophils in Omalizumab IgE Reduces exacerbations FDA approved blood Improves symptoms and EMA and Periostin quality of life
[0080] FENO
[0081] Eosinophils in Mepolizumab IL-5 Reduces the number of FDA-approved blood / sputum eosinophils, exacerbations and Under Evaluation by FENO OCS EMA
[0082] Improved FEV ¹ Tested for CRSwNP Eosinophils in Reslizumab IL-5 Reduces the number of Under evaluation for blood eosinophils, FDA exacerbations
[0083] FEV ⁱ improvement
[0084] Eosinophils in Benralizumab IL- Reduces the number of Phase III blood 5Ra eosinophils and basophils,
[0085] exacerbations
[0086] FEV ⁱ improvement
[0087] Eosinophils in Dupilumab IL- Reduces exacerbations Phase III blood 4Ra Improves FEV ⁱ Tested for Improves symptoms and CRSwNP, AD and quality of life EoE Periostin Tralokinumab IL-13 Reduces the number of Phase II
[0088] DPP-4 eosinophils and exacerbations
[0089] FEV ⁱ improvement
[0090] Periostin Lebrikizumab IL-13 Reduces exacerbations Phase III Better FEVi
[0091] The IgE, IL-5, and IL-4 / IL-13 pathways can be approached with monoclonal antibodies (mAbs). There is a notable overlap between the so-called predictive biomarkers and significant heterogeneity in the clinical response. CRSwNP, Chronic rhinosinusitis with nasal polyps; DPP-4, dipeptidyl peptidase 4; EMA, European Medicines Agency; EoE, eosinophilic esophagitis; FDA, United States Food and Drug Administration; IL-4Ra, IL-4 receptor a; IL-5Ra, IL-5 receptor a; OCS, oral corticosteroids.
[0092]
[0093] On the other hand, although allergic asthma (AA) affects a significant proportion of patients, from 10% to 33% of subjects with asthma, they are defined as non-allergic (NA) subjects. as subjects with asthma but without any associated allergic sensitization. In these subjects, the mechanisms that contribute to the type 2 immune response are less clear. In many cases, instead of eosinophilic inflammation, there is a prevalence of neutrophils. The endotype of non-Th2-mediated immune response asthma is much less well-known than that of the Th2-type and until now no effective targeted therapies against this endotype have been demonstrated. Therefore, efforts directed at this type of asthma are clearly an unmet need and biologically targeted therapies are an area to be developed.
[0094]
[0095] Brief description of the figures
[0096]
[0097] Fig. 1. Preliminary study of expression data by PCA ( Principal Component Assay) as explained in Example 1, particularly in the gene expression study section.
[0098]
[0099] Fig. 2 . Quantification of MSR1. Relative quantification of the 2 bands detected by the MSR1 antibody of all the subjects studied in the control group (C) and the group with non-allergic asthma (ANA). * Statistically significant comparison (p <0.001) between the group with non-allergic asthma and the control group.
[0100]
[0101] Fig. 3. SERPINB2 quantification. Relative quantification of the band detected around 43kDa by the SERPINB2 antibody of all the subjects studied for this control group protein (C), non-allergic asthma (ANA), allergic asthma (AA) and allergy without asthma (A). * Statistically significant comparison (p <0.0001) between the control and indicated group. Statistically significant comparison (p <0.05) between the group with allergy without asthma and the indicated one.
[0102]
[0103] Fig. 4 . PHLDA quantification 1. Relative quantification of the band detected around 43kDa by the PHLDA1 antibody of all the subjects studied for this control group protein (C), non-allergic asthma (ANA), allergic asthma (AA) and allergy without asthma (A).
[0104]
[0105] Fig. 5 . Whey protein levels . A) Mean levels of IL8 in the serum of the control groups (C), non-allergic asthma (ANA), allergic asthma (AA) and allergy without asthma (A). B) Average levels of IL10 in the serum of groups C, ANA, AA and A. C) Average levels of CHI3L1 in the serum of groups C, ANA, AA and A. D) Average levels of PI3 in the serum of groups C, ANA, AA and A. D) Mean serum POSTN levels of groups C, ANA, AA and A.
[0106] * Statistically significant comparison (p <0.001) between group A and the indicated group. Statistically significant comparison (p <0.0001) between group C and the indicated group. ** Statistically significant comparison (p <0.05) between the indicated groups - ## Statistically significant comparison (p <0.001) between the indicated groups.
[0107]
[0108] Description of the Invention
[0109]
[0110] Definitions
[0111]
[0112] For the purposes of the present invention, the following definitions are included below:
[0113]
[0114] - In the present invention, by "Asthma" is meant a chronic inflammatory disease of the respiratory tract, in whose pathogenesis various cells and mediators of inflammation intervene, conditioned in part by genetic factors and which is associated with bronchial hyperresponsiveness (HRB) and a Variable obstruction of air flow, totally or partially reversible, either by the action of drugs or spontaneously.- In the present invention, by "non-allergic asthma" is understood the clinical diagnosis of asthma made by a specialist allergist or pulmonologist, according to the criteria of the Spanish Asthma Management Guide (GEMA) and without any associated allergic symptoms (medical history not suspected of any allergy and negative skin tests against battery of common allergens).
[0115] - In the present invention, by "allergic asthma" is meant the clinical diagnosis of asthma made by an allergist or a specialist pulmonologist, according to the criteria of the Spanish Guide to Asthma Management (GEMA), associated with characterized allergic symptoms (history of suspicion of allergic diseases, positive skin tests against an allergen from a battery of common allergens, high total IgE).
[0116] - the term "selection" is understood as the examination or testing of a group of individuals belonging to the general population, at risk of suffering from asthma, with the aim of distinguishing healthy or allergic individuals from those with asthma, more particularly with the objective of distinguishing the severity of asthma among those individuals who suffer from asthma.
[0117] - The expression "positively regulated", "increased concentration level" or "overexpressed" referred to any of the proteins or combinations thereof described in the present invention, refers to an increase in its level of protein concentration with respect to a given "threshold value" or "limit value" of at least 5%, of at least 10%, of at least 15%, of at least 20%, of at least 25 %, of at least 30%, of at least 35%, of at least 40%, of at least 45%, of at least 50%, of at least 55%, of at least more than one 60%, of at least more than 65%, of at least 70%, of at least 75%, of at least 80%, of at least 85%, of at least 90%, of at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, or more.
[0118] - The expression "negatively regulated", "reduced concentration level" or "under-expressed" referred to any of the proteins or combinations thereof described in the present invention, refers to a reduction in its level of protein concentration with respect to to a given "threshold value" or "limit value" of at least 5%, of at least 10%, of at least 15%, of at least 20%, of at least 25%, of at least 30%, of at least 35%, of at least 40%, of at least 45%, of at least 50%, of at least 55%, of at least more than 60%, of at less than 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, of at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, or more.
[0119] - In the present specification, in order to separate the integer from the decimals, the Anglo-Saxon mode is used, therefore using a period instead of a comma.
[0120] - The term "threshold value" or "limit value", when referring to the concentration levels of the proteins described in the present invention, refers to a reference concentration level indicative that a subject is likely to have asthma or a type of asthma determined as intermittent asthma or persistent mild, moderate, or severe asthma with given sensitivity and specificity if the patient's concentration levels are above or below those threshold, limit, or reference levels.
[0121] - The expression "comprising" is intended to include, but is not limited to, what follows the expression "comprising". Therefore, the use of the term "comprising" indicates that the cited elements are necessary or mandatory, but that other elements are optional and there is a possibility that they may or may not be present.
[0122] - By "consisting of" it is understood that it includes, and is limited to, what follows the expression "consisting of". Therefore, the expression "consisting of" indicates that the cited elements are necessary or mandatory and that no other element can be present.
[0123] - It should also be noted that the term "kit", as used herein, is not limited to any specific device and includes any device suitable for practicing the invention.
[0124] - SERPINB2 (member of the group of inhibitors of the serine protease family, enzymes that inhibit protease cathepsin G of neutrophils and mast cell chymase. SERPINB2 has been detected in different types of cells, playing a role in inflammation and remodeling ( Swartz, JM, Bystrom, J., Dyer, KD, Nitto, T., Wynn, TA, Rosenberg, HF, 2004. Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J. Leukoc.Biol. 76, 812-819).
[0125] - MSR1 (Class A macrophage "junk" receptor, also called SR-A or CD204. These receptors are integral trimeric membrane glycoproteins, initially described as macrophage specific (Naito, M., Kodama, T., Matsumoto, A ., Doi, T., Takahashi, K., 1991. Tissue distribution, intracellular localization, and in vitro expression of bovine macrophage scavenger receptors. Am. J. Pathol. 139, 1411-1423), which have been implicated in many processes Physiological and pathological factors associated with this cell type Later, they were also found in other types of cells (usually of tissue localization), such as vascular smooth muscle cells, endothelial cells (EC), human lung epithelial cells, etc. (Tomokiyo, R. , Jinnouchi, K., Honda, M., Wada, Y., Hanada, N., Hiraoka, T., et al., 2002. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosc lerosis 161, 123-132), a fact that increases its pathophysiological potential, indicated as a central pivot of health and disease (Kelley, JL, Ozment, TR, Li, C., Schweitzer, JB, Williams, DL, 2014. Scavenger Receptor -A (CD204): a twoedged sword in health and disease. Crit. Rev. Immunol. 34, 241-261).
[0126] - Lower MSR1 (lower molecular weight band recognized by the specific monoclonal antibody of human MSR1, in the western protein analysis ).
[0127] - Higher MSR1 (band of higher molecular weight recognized, by the specific monoclonal antibody of human MSR1, in the western protein analysis ).
[0128] - PHLDA1 (pleckstrin homology-like domain, family A, member 1, a proline-histidine-rich nuclear protein that has been described in humans as a putative marker of epithelial stem cells in the intestine (Sakthianandeswaren, A., Christie, M., D'Andreti, C., Tsui, C., Jorissen, RN, Li, S., et al., 2011. PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. Cancer Res. 71, 3709-3719) .
[0129] - CHI3L1 ( chitinase 3-like 1, a glycoprotein, a member of the 18 family of glycosyl transferases or YKL-40. It lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils, and synovial fluid cells. The role of tissue remodeling and inflammation and its role as a possible biomarker has been reviewed in signaling mechanisms regulated by YKL-40.
[0130] - IL10 (Cytokine with pleiotropic effects, produced mainly by monocytes and to a lesser extent by lymphocytes, which has been described as a potential controller of the immune response.
[0131] - IL8 (Interleukin 8, or member of the CXC family of chemokines, considered one of the main mediators of the inflammatory response and very important for the survival and chemotaxis of neutrophils. It is secreted by various cell types and is considered related to the pathogenesis of bronchiolitis, a respiratory disease caused by viral infection, as well as implicated in acute lung damage, for affecting, among other things, the survival of neutrophils - PI3 (Peptidase 3 inhibitor derived from the skin or specific inhibitor of elastase (Trappin-2 or Elafin) that works as an antimicrobial peptide. It is a potent serine protease inhibitor, thus preventing excessive damage to inflammatory sites. It modulates a wide range of parameters that are critical to inflammation, although with pleiotropic effects and / or Periostin (Secreted protein composed of 4 domains of fascillin 1 aligned in tandem, which is suspected ha is an adhesion molecule and may be involved in subepithelial fibrosis.
[0132] A variety of statistical and mathematical methods for establishing the threshold level or concentration limit are known in the prior art. A threshold or limit concentration level for a particular biomarker can be selected, for example, based on data from the Receptor Operational Characteristics (ROC) graphs, as described in the Examples and Figures of the present invention. One of skill in the art will appreciate that these threshold or limit concentration levels can be varied, for example, by moving along the ROC graph for any of the biomarkers described in the present invention, or for any combination thereof, to obtain different values. sensitivity or specificity, thus affecting the overall performance of the assay. For example, if the goal is to have a clinically sound diagnostic method, high sensitivity should be attempted. However, if the goal is to have an inexpensive method, one should try to achieve high specificity. The best limit refers to the value obtained from the ROC graph for a particular biomarker, or a particular combination, that produces the best sensitivity and specificity. The values of Sensitivity and specificity are calculated over the range of thresholds (limits). In this way, the threshold or limit values can be selected such that the sensitivity and / or specificity are at least about 70%, and can be, for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% in at least 60% of the patient population tested, or at least 65%, 70%, 75% or 80% of the patient population tested.
[0133]
[0134] Accordingly, each of the embodiments cited throughout the present invention is preferably performed by determining the concentration levels of at least one of the biomarkers described in the present invention in a sample isolated from a subject to be diagnosed or screened, and comparing the concentration levels of said biomarker with predetermined threshold or limit values.
[0135]
[0136] Detailed description of the invention
[0137]
[0138] Considering the previous knowledge, the present invention aims to provide new markers and / or combinations of biomarkers, capable of defining in simple samples to analyze, preferably derived from peripheral blood such as serum, plasma or proteins derived from PBMCs, as well as sputum or other biological sample of the target organ (by target organ is meant lung or any part of the pathways areas of a human subject), differential patient groups of 3 clinical phenotypes: AA (Allergic Asthma), ANA (Non-Allergic Asthma) and Allergy without asthma (A), as well as potential markers capable of differentiating gravity.
[0139]
[0140] In the present invention, therefore, the utility of studying the expression of 8 proteins, 5 in serum and 3 by westem-blot (as described in the examples of the invention), as potential differential biomarkers of various clinical phenotypes: Non-Allergic Asthma (ANA), Allergic Asthma (AA) and Allergy without asthma (A), as well as, of differential biomarkers of severity in asthma: ANA Severe vs ANA Moderate / mild (M / l) and AA Severe vs AA Moderate / slight (M / l). Likewise, the present invention provides a series of biomarkers capable of discriminating between different clinical phenotypes as illustrated throughout the description.
[0141]
[0142] To define the specific biomarkers of each condition, an analysis of ROC curves (quantitative) has been performed, which allows us to define an ideal threshold for discrimination and qualitative) of protein expression, comparing the AUC of the potential biomarkers individually and combining them two by two or three by three.
[0143]
[0144] The comparisons made are:
[0145]
[0146] 1. Each clinical phenotype (total ANA, total AA and A) with respect to the control group.
[0147] 2. Each sub-phenotype of asthmatics according to severity:
[0148] to. Moderate / mild compared to control
[0149] b. Serious about control
[0150] c. Moderate / mild compared to Severe
[0151]
[0152] 3. In addition, the clinical phenotypes have been compared with each other: total ANA vs total AA, ANA Grave vs AA Grave, ANA M / L vs AA M / L, total AA vs A, AA Grave vs A, AA M / L vs A .
[0153]
[0154] We attached the results tables of all the biomarkers analyzed, indicating only the results that give a good (AUC: 0.75-0.9), very good (AUC: 0.9-0.97) or excellent (AUC: 0.97-1) quantitative ROC curve. . The quantitative AUC value criterion has been chosen because it allows us to define separation thresholds between groups, in an objective way and therefore, it would be useful for future kits.
[0155]
[0156] BIOMARKERS FOR NON-ALLERGIC ASTHMA (ANA)
[0157]
[0158] 1. Comparisons between healthy controls and non-allergic asthmatics (total population) (ANA)
[0159]
[0160] - N0 = Group observations Control
[0161] - N1 = Observations in Non-allergic Asthmatic Group (ANA)
[0162] - AUC: Area Under the ROC Curve at a quantitative level. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0163] Table 5. Individual ROC Curves
[0164]
[0165] Variable N0 N1 AUC (95% CI) Threshold
[0166] CHI3L1 30 30 0.60 (0.45 - 0.75) 13064
[0167] IL10 9 11 0.42 (0.15 -0.70) 102.9
[0168] IL8 9 14 0.50 (0.25 - 0.75) 39
[0169] PI3 30 29 0.50 (0.35 - 0.65) 6528
[0170] Periostin 30 30 0.62 (0.48 - 0.77) 13633
[0171] Upper MSR1 9 18 0.60 (0.38 -0.81) 0.208
[0172] Lower MSR1 9 18 0.96 (0.89 - 1.00) 0.148
[0173] PHLDA1 8 5 0.42 (0.07 - 0.78) 0.011
[0174] SERPINB2 6 11 0.91 (0.72 - 1.00) 0.404
[0175]
[0176] The threshold value is only detailed here, at the individual level, because it will be the same for each biomarker, even if it is combined.
[0177] Table 6. ROC curves for models with combinations of two variables Variables Variables Combination N0 N1 quantitative qualitative CHI3L1 + IL10 9 11 0.48 (0.20 - 0.77) 0.63 (0.37 - 0.89) CHI3L1 + IL8 9 14 0.67 (0.44 -0.91) 0.64 (0.43 - 0.84) CHI3L1 + PI3 30 29 0.59 (0.44 - 0.74) 0.70 (0.57 - 0.82) CHI3L1 + Periostina 30 30 0.63 (0.49 - 0.78) 0.72 (0.60 - 0.85) CHI3L1 MSR1 higher 9 18 0.78 (0.60 - 0.95) 0.84 ( 0.71 - 0.98) CHI3L1 Lower MSR1 9 18 0.97 (0.91 - 1.00) 0.99 (0.97 - 1.00) CHI3L1 + PHLDA1 8 5 0.70 (0.39 - 1.00) 0.68 (0.37 - 0.98) CHI3L1 SERPINB2 6 11 0.92 (0.77 - 1.00) 0.92 ( 0.78 - 1.00) IL10 + PI3 9 11 0.59 (0.32 - 0.85) 0.58 (0.33 - 0.82) IL10 + Periostina 9 11 0.47 (0.19 -0.76) 0.64 (0.39 - 0.89) IL8 + PI3 9 14 0.61 (0.37 - 0.85) 0.70 (0.53 - 0.87) IL8 + Periostina 9 14 0.74 (0.52 - 0.95) 0.74 (0.59 - 0.89) PI3 + Periostina 30 29 0.67 (0.53 - 0.82) 0.69 (0.56 - 0.82) PI3 + MSR1 superior 9 17 0.63 (0.41 - 0.84 ) 0.73 (0.56 - 0.89) PI3 Lower MSR1 9 17 0.96 (0.88 - 1.00) 0.99 (0.98 - 1.00 ) PI3 + PHLDA1 8 5 0.47 (0.09 - 0.86) 0.75 (0.50 - 1.00) PI3 SERPINB2 6 11 0.91 (0.72 - 1.00) 0.96 (0.88 - 1.00) Periostin + upper MSRI 9 18 0.73 (0.54 - 0.93) 0.75 (0.63 - 0.87) Periostin lower MSR1 9 18 0.96 (0.89 - 1.00) 0.97 (0.92 - 1.00) Periostin PHLDA1 8 5 0.82 (0.59 - 1.00) 0.81 (0.50 - 1.00) Periostin SERPINB2 6 11 0.95 (0.85 - 1.00) 0.98 (0.95 - 1.00 ) Table 7. ROC curves for models with combinations of three variables
[0178]
[0179] Variables Variables Variable N0 N1 quantitative qualitative
[0180] CHI3L1 IL10 Periostin 9 11 0.53 (0.25 - 0.80) 0.73 (0.50 - 0.95)
[0181] CHI3L1 IL8 Periostin 9 14 0.72 (0.50 - 0.94) 0.75 (0.55 - 0.94) CHI3L1 PI3 Periostin 30 29
[0182]
[0183] CHI3L1 Periostin MSR1 upper 9 18
[0184]
[0185] Based on the information presented in Tables 5 to 7, we propose, as the first aspect of the invention, an in vitro method to select subjects at risk of suffering from non-allergic asthma, comprising: (a) measuring the pattern or level of concentration of al minus one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level or with the concentration level of a healthy subject, where differences in concentration of at least one of said protein biomarkers is indicative that said subject is at risk for non-allergic asthma. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 5 clearly indicates when the overexpression or underexpression of each of the biomarkers is indicative that said subject is at risk of developing non-allergic asthma. On the other hand, Tables 6 and 7 indicate specific combinations of biomarkers useful in determining the risk of developing non-allergic asthma. Each of said combinations is part and can be implemented in the method proposed in the first aspect of the invention.
[0186]
[0187] A preferred embodiment of the first aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having non-allergic asthma, comprising steps a) and b) of the first aspect of the invention, and optionally (c) confirm the presence of asthma by means of a clinical examination.
[0188]
[0189] Another preferred embodiment of the first aspect of the invention relates to an in vitro method for monitoring the response to a therapy or for monitoring the progression of non-allergic asthma, in a subject suffering from said disease, comprising steps a) and b) of the first aspect of the invention.
[0190]
[0191] Another preferred embodiment of the first aspect of the invention relates to a method of treating subjects suffering from non-allergic asthma, comprising steps a) and b) of the first aspect of the invention, and (c) treating the patient who has been treated. diagnosed non-allergic asthma. It is noted that possible therapies are expressly mentioned throughout the description, in particular control or maintenance medications are particularly useful, which must be administered daily for prolonged periods, include inhaled glucocorticoids (GCI) or systemic, antagonists of leukotrienes (ARLT), long-acting p2-adrenergic agonists (LABA), tiotropium and monoclonal anti-IgE antibodies (omalizumab). Chromones and delayed release theophylline could also be useful therapy in this type of pathology. Relief medications may also be used on demand to treat or prevent bronchoconstriction quickly, including inhaled short-acting p2-adrenergic agonists (SABAs) (of choice) and inhaled anticholinergics (ipratropium bromide). ). In the event of severe asthma, there may be a need to require multiple drugs and high doses for treatment.
[0192]
[0193] Another preferred embodiment of the first aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group consisting of a minimally invasive biological sample from the subjects to be selected, such as a blood sample (such as a whole blood sample) or derived from peripheral blood such as serum, plasma or proteins derived from PBMCs, as well as, sputum or other biological sample of the target organ (by target organ is meant lung or any part of the airways of a human subject). Preferably, the subject is a human subject.
[0194]
[0195] Additionally, and again, as a result of the information presented in Tables 5 to 7, we propose as a second aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the first aspect of the invention, where differences in expression of at least one of the mentioned biomarkers is indicative of risk of having non-allergic asthma, to diagnose in vitro the risk of having non-allergic asthma.
[0196]
[0197] A preferred embodiment of the second aspect of the invention refers to the use of the kit, where the kit described in the previous paragraph can be implemented or used to carry out the present invention using any technique suitable for it. In this sense, various techniques capable of implementing or practicing the present invention are well known in the state of the art. Below I detail some of them: formation of immuno-precipitates alone or combined with diffusion and / or electrophoresis (Western-blot), colorimetric techniques, or direct measurement of the binding of the antibody to the antigen (ELISAS). All of these principles are used in one way or another in kits that are commercially available for diagnosing disease and can be easily implemented in the present invention.
[0198]
[0199] 2. Comparisons between controls and mild or moderate non-allergic asthma (ANA)
[0200]
[0201] - N0 = Group observations Control
[0202] - N1 = Group Observations ANA Moderate / slight
[0203] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0204] Table 8. Individual ROC curves
[0205] Variable N0 N1 AUC (95% CI) Threshold
[0206] CHI3L1 30 15 0.56 (0.39 - 0.73) 13064
[0207] IL10 9 6 0.41 (0.08 - 0.74) 102.9
[0208] IL8 9 7 0.62 (0.30 - 0.94) 677
[0209] PI3 30 15 0.51 (0.34 - 0.69) 3074
[0210] Periostin 30 15 0.69 (0.52 - 0.86) 15787
[0211] Upper MSR1 9 8 0.60 (0.29 - 0.90) 0.208
[0212] Lower MSR1 9 8 1.00 (1.00 - 1.00) 0.148
[0213] PHLDA1 8 7 0.48 (0.15 -0.81) 0.014
[0214] SERPINB2 6 6 0.89 (0.66 - 1.00) 0.404
[0215]
[0216] Table 9. ROC curves for models with combinations of two variables.
[0217] Variables Variables Combination N0 N1 quantitative qualitative CHI3L1 + IL10 9 6 0.41 (0.08 - 0.74) 0.73 (0.45 - 1.00) CHI3L1 IL8 9 7 0.63 (0.32 - 0.95) 0.77 (0.54 - 1.00) CHI3L1 + PI3 30 15 0.56 (0.39 - 0.73 ) 0.71 (0.60 -0.81) CHI3L1 Periostina 30 15 0.70 (0.53 - 0.86) 0.81 (0.68 - 0.94) CHI3L1 MSR1 superior 9 8 0.83 (0.63 - 1.00) 0.90 (0.78 - 1.00) CHI3L1 SERPINB2 6 6 0.97 (0.90 - 1.00) 0.92 (0.75 - 1.00) IL10 + PI3 9 6 0.67 (0.35 - 0.99) 0.67 (0.40 - 0.94) IL10 + Periostin 9 6 0.63 (0.32 - 0.94) 0.74 (0.49 - 0.99) IL8 PI3 9 7 0.76 (0.50 - 1.00) 0.90 (0.79 - 1.00) IL8 Periostina 9 7 0.87 (0.70 - 1.00) 0.90 (0.79 - 1.00) PI3 + Periostina 30 15 0.69 (0.52 - 0.86) 0.73 (0.61 - 0.86) PI3 MSR1 superior 9 8 0.61 (0.32 - 0.90) 0.81 (0.60 - 1.00) PI3 SERPINB2 6 6 0.89 (0.66 - 1.00) 0.97 (0.91 - 1.00) Periostina MSR1 superior 9 8 0.81 (0.58 - 1.00) 0.80 (0.60 - 1.00) Periostina SERPINB2 6 6 0.97 (0.90 - 1.00) 0.99 (0.95 - 1.00) Table 10. ROC curves for models with combinations of three variables
[0218] Variables Variables Variable N0 N1 quantitative qualitative
[0219] CHI3L1 IL10 Periostin 9 6 0.63 (0.31 - 0.95) 0.80 (0.57 - 1.00)
[0220] CHI3L1 IL8 Periostina 9 7 0.87 (0.70 - 1.00) 0.91 (0.79 - 1.00) CHI3L1 PI3 Periostina 30 15 0.68 (0.51 - 0.85) 0.82 (0.70 - 0.94) CHI3L1 PI3 MSR1 superior 9 8 0.83 (0.63 - 1.00) 0.92 (0.81 - 1.00)
[0221] CHI3L1 Periostina MSR1 superior 9 8 0.88 (0.71 - 1.00) 0.98 (0.93 - 1.00) CHI3L1 Periostina SERPINB2 6 6 0.99 (0.95 -1.00) IL10 PI3 Periostina 9 6 0.61 (0.29 - 0.93) 0.77 (0.52 - 1.00) IL8 PI3 Periostina 9 7 0.84 (0.64 - 1.00) 0.97 (0.90 - 1.00) PI3 Periostina MSR1 superior 9 8 0.81 (0.58 - 1.00) 0.88 (0.74 - 1.00) PI3 Periostina SERPINB2 6 6 0.97 (0.90 - 1.00) 0.99 (0.95 -1.00)
[0222]
[0223] Based on the information presented in Tables 8 to 10, we propose, as a third aspect of the invention, an in vitro method to select subjects at risk of suffering non-allergic asthma with mild or moderate persistence, comprising: (a) measuring the pattern or concentration level of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level or with the concentration level of a healthy subject, where differences in concentration of at least one of said protein biomarkers is indicative that said subject is at risk of developing non-allergic asthma with mild or moderate persistence. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 8 clearly indicates when the overexpression or under-expression of each of the biomarkers is indicative that said subject is at risk of developing non-allergic asthma with mild or moderate persistence. On the other hand, Tables 9 and 10 indicate specific combinations of biomarkers useful in determining the risk of suffering from non-asthma. allergic with mild or moderate persistence. Each of said combinations is part of and can be implemented in the method proposed in the third aspect of the invention.
[0224]
[0225] A preferred embodiment of the third aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having mild or moderate persistent non-allergic asthma, comprising steps a) and b) of the first aspect of the invention, and optionally (c) confirm the presence of non-allergic asthma with mild or moderate persistence by means of a clinical examination.
[0226]
[0227] Another preferred embodiment of the third aspect of the invention relates to an in vitro method for monitoring the response to a therapy or for monitoring the progression of non-allergic asthma with mild or moderate persistence, in a subject suffering from said disease, comprising the steps a) and b) of the third aspect of the invention.
[0228]
[0229] Another preferred embodiment of the third aspect of the invention relates to a method of treating subjects suffering from mild or moderate persistent non-allergic asthma, comprising steps a) and b) of the third aspect of the invention, and (c) treating the patient who has been diagnosed with non-allergic asthma with mild or moderate persistence. It is noted that possible therapies are expressly mentioned throughout the description, in particular in the first aspect of the invention.
[0230]
[0231] Another preferred embodiment of the third aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of biological samples detailed in the first aspect of the invention.
[0232]
[0233] Additionally, and again, as a result of the information presented in Tables 8 to 10, we propose as a fourth aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the third aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is indicative of the risk of having non-allergic asthma with mild or moderate persistence, to diagnose in vitro the risk of having non-allergic asthma with mild or moderate persistence.
[0234]
[0235] A preferred embodiment of the fourth aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0236] ^ Comparisons between controls and severe non-allergic asthma (ANA)
[0237]
[0238] - N0 = Group observations Control
[0239] - N1 = Observations in Group ANA Serious
[0240] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0241]
[0242] Table 11. Individual ROC curves
[0243] Variable N0 N1 AUC (95% CI) Threshold
[0244] CHI3L1 30 15 0.63 (0.45 -0.81) 14367
[0245] IL10 9 5 0.56 (0.23 - 0.88) 32.5
[0246] IL8 9 7 0.62 (0.28 - 0.96) 262
[0247] PI3 30 14 0.52 (0.33 -0.71) 6528
[0248] Periostin 30 15 0.55 (0.37 - 0.74) 13633
[0249] Upper MSR1 9 10 0.60 (0.31 - 0.89) 0.254
[0250] Lower MSR1 9 10 0.93 (0.80 - 1.00) 0.137
[0251] PHLDA1 8 7 0.48 (0.15 -0.81) 0.014
[0252] SERPINB2 6 5 0.93 (0.78 - 1.00) 0.359
[0253] Table 12. ROC curves for models with combinations of two variables.
[0254] Variables Variables Combination N0 N1 qualitative quantitative CHI3L1 + IL10 9 5 0.62 (0.30 - 0.94) 0.77 (0.54 - 0.99) CHI3L1 + IL8 9 7 0.67 (0.37 - 0.96) 0.78 (0.55 - 1.00) CHI3L1 + PI3 30 14 0.63 (0.45 - 0.81) 0.68 (0.53 - 0.84) CHI3L1 + Periostina 30 15 0.64 (0.46 - 0.82) 0.72 (0.57 - 0.88) CHI3L1 MSR1 upper 9 10 0.76 (0.50 - 1.00) 0.83 (0.66 - 1.00) CHI3L1 MSR1 lower 9 10 0.94 (0.83 - 1.00) 0.99 (0.96 - 1.00) CHI3L1 SERPINB2 6 5 0.93 (0.78 - 1.00) 0.93 (0.80 - 1.00) IL10 + PI3 9 5 0.51 (0.18 -0.84) 0.70 (0.44 - 0.96) IL10 Periostin 9 5 0.60 (0.23 - 0.97) 0.93 (0.80 - 1.00) IL8 PI3 9 7 0.46 (0.15 -0.77) 0.77 (0.54 - 1.00) IL8 + Periostina 9 7 0.57 (0.27 - 0.88) 0.76 (0.51 - 1.00) PI3 + Periostina 30 14 0.65 (0.47 - 0.84) 0.71 (0.56 - 0.86) PI3 + MSR1 upper 9 9 0.64 (0.35 - 0.93) 0.78 (0.56 - 1.00) PI3 MSR1 lower 9 9 0.95 (0.85 - 1.00) 0.99 (0.96 - 1.00) PI3 SERPINB2 6 5 0.93 (0.78 - 1.00) 0.97 (0.89 - 1.00) Periostin MSR1 superior 9 10 0.66 (0.38 - 0.93) 0.75 (0.59 -0.91) Periostin Lower MSR1 9 10 0.93 (0.80 - 1.00) 0.95 (0.85 - 1.00) Periostin SERPINB2 6 5 0.97 (0.87 - 1.00) 0.98 (0.94 - 1.00) Table 13. ROC curves for models with combinations of three variables
[0255] Variables Variables Variable N0 N1 quantitative qualitative
[0256] CHI3L1 IL10 Periostin 9 5 0.64 (0.33 - 0.96) 0.97 (0.89 - 1.00)
[0257] CHI3L1 IL8 Periostina 9 7 0.67 (0.37 - 0.96) 0.84 (0.63 - 1.00) CHI3L1 PI3 Periostina 30 14 0.62 (0.43 - 0.81) 0.80 (0.65 - 0.94) CHI3L1 PI3 MSR1 superior 9 9 0.64 (0.34 - 0.94) 0.94 (0.84 - 1.00) CHI3L1 PI3 MSR1 lower 9 9 0.95 (0.86 - 1.00)
[0258]
[0259] CHI3L1 Periostin upper MSR1 9 10 0.76 (0.50 - 1.00) 0.84 (0.68 - 1.00) CHI3L1 Periostin lower MSR1 9 10 0.94 (0.84 - 1.00) 0.99 (0.96 -1.00) IL10 PI3 Periostin 9 5 0.60 (0.22 - 0.98) 0.97 (0.89 - 1.00) IL8 PI3 Periostin 9 7 0.62 (0.32 - 0.92) 0.76 (0.51 - 1.00) PI3 Periostin upper MSR1 9 9 0.77 (0.54 - 0.99) 0.87 (0.70 - 1.00) PI3 Periostin Lower MSR1 9 9 0.96 (0.88 - 1.00) 0.99 (0.96 -1.00 )
[0260]
[0261] Based on the information set forth in Tables 11 to 13, we propose, as the fifth aspect of the invention, an in vitro method to select subjects at risk of suffering non-allergic asthma with severe persistence that includes: (a) measuring the pattern or level of concentration of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level or with the concentration level of a healthy subject, where differences in concentration of at least one of said protein biomarkers is indicative that said subject is at risk of suffering non-allergic asthma with severe persistence. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 11 clearly indicates when the overexpression or under expression of each of the biomarkers is indicative that said subject is at risk of suffering non-allergic asthma with severe persistence. On the other hand, Tables 12 and 13 indicate specific combinations of biomarkers useful in determining the risk of suffering non-allergic asthma with severe persistence. Each of these combinations it is part of and can be implemented in the method proposed in the fifth aspect of the invention.
[0262]
[0263] A preferred embodiment of the fifth aspect of the invention relates to an in vitro method for diagnosis / prognosis of a subject suspected of having severe persistent non-allergic asthma, comprising steps a) and b) of the fifth aspect of the invention, and optionally (c) confirming the presence of non-allergic asthma with severe persistence by means of a clinical examination.
[0264]
[0265] Another preferred embodiment of the fifth aspect of the invention refers to an in vitro method to monitor the response to a therapy or to monitor the progression of non-allergic asthma with severe persistence, in a subject suffering from said disease, comprising the steps a ) and b) of the fifth aspect of the invention.
[0266]
[0267] Another preferred embodiment of the fifth aspect of the invention relates to a method of treating subjects suffering from severe persistent non-allergic asthma, comprising steps a) and b) of the fifth aspect of the invention, and (c) treating the patient in whom He has been diagnosed with non-allergic asthma with severe persistence. It is noted that possible therapies are expressly mentioned throughout the description, in particular in the first aspect of the invention.
[0268]
[0269] Another preferred embodiment of the fifth aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of biological samples provided in the first aspect of the invention.
[0270]
[0271] Additionally, and again, based on the information set forth in Tables 11 to 13, we propose as a sixth aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the fifth aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is indicative of the risk of having non-allergic asthma with severe persistence, to diagnose in vitro the risk of having non-allergic asthma with severe persistence .
[0272]
[0273] A preferred embodiment of the sixth aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0274] 4. Comparisons between mild / moderate and severe non-allergic asthma (ANA)
[0275]
[0276] - N0 = Observations in group ANA mild / moderate
[0277] - N1 = Observations in Group ANA Serious
[0278] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0279]
[0280] Table 14. Individual ROC curves
[0281] Variable N0 N1 AUC (95% CI) Threshold
[0282] CHI3L1 15 15 0.62 (0.40 - 0.83) 18500
[0283] IL10 6 5 0.47 (0.07 - 0.86) 105.2
[0284] IL8 7 7 0.76 (0.49 - 1.00) 841
[0285] PI3 15 14 0.55 (0.33 - 0.78) 4845
[0286] Periostin 15 15 0.65 (0.44 - 0.86) 17419
[0287] Upper MSR1 8 10 0.46 (0.17 -0.75) 0.257
[0288] Lower MSR1 8 10 0.55 (0.27 - 0.83) 0.056
[0289] PHLDA1 8 7 0.48 (0.15 -0.81) 0.014
[0290] SERPINB2 6 5 0.70 (0.32 - 1.00) 0.132
[0291] Table 15. ROC curves for models with combinations of two variables
[0292] Variables Variables Combination N0 N1 quantitative qualitative CHI3L1 + IL10 6 5 0.43 (0.05 -0.81) 0.65 (0.29 - 1.00) CHI3L1 IL8 7 7 0.76 (0.49 - 1.00) 0.85 (0.65 - 1.00) CHI3L1 + PI3 15 14 0.56 (0.33 - 0.79 ) 0.68 (0.48 - 0.87) CHI3L1 Periostin 15 15 0.77 (0.59 - 0.96) 0.75 (0.57 - 0.94) CHI3L1 + upper MSR1 8 10 0.68 (0.41 - 0.94) 0.73 (0.51 - 0.94) CHI3L1 + lower MSR1 8 10 0.65 (0.37 - 0.93) 0.73 (0.51 - 0.94) CHI3L1 + SERPINB2 6 5 0.63 (0.25 - 1.00) 0.90 (0.75 - 1.00) IL10 + PI3 6 5 0.63 (0.25 - 1.00) 0.83 (0.60 - 1.00) IL10 Periostin 6 5 0.77 (0.43 - 1.00) 0.90 (0.73 - 1.00) IL8 PI3 7 7 0.82 (0.58 - 1.00) 0.96 (0.87 - 1.00) IL8 Periostina 7 7 0.78 (0.52 - 1.00) 0.96 (0.87 - 1.00) PI3 + Periostina 15 14 0.57 (0.34 - 0.80) 0.73 (0.55 - 0.92) PI3 + MSR1 upper 8 9 0.60 (0.30 - 0.90) 0.67 (0.42 - 0.93) PI3 + MSR1 lower 8 9 0.60 (0.30 - 0.90) 0.74 (0.49 - 1.00) PI3 SERPINB2 6 5 0.73 ( 0.39 - 1.00) 0.93 (0.82 - 1.00) Periostin + upper MSR1 8 10 0.64 (0.36 - 0.92) 0.72 (0.50 - 0.95) Periost ina Lower MSR1 8 10 0.62 (0.35 - 0.90) 0.81 (0.60 - 1.00) Periostin SERPINB2 6 5 0.90 (0.71 - 1.00) 0.97 (0.89 - 1.00) Upper MSR1 + Lower MSR1 8 10 0.55 (0.26 - 0.84) 0.66 (0.41 - 0.92) Table 16. ROC curves for models with combinations of three variables
[0293] Variables Variables Variable N0 N1 quantitative qualitative
[0294] CHI3L1 IL10 Periostin 6 5 0.77 (0.46 - ■ 1.00) 0.92 (0.76 - ■ 1.00)
[0295] CHI3L1 IL8 Periostina 7 7 0.98 (0.92 --1.00) 0.99 (0.96 --1.00) CHI3L1 PI3 Periostina 15 14 0.76 (0.57 - 0.95) 0.76 (0.58 - ■ 0.94) CHI3L1 PI3 MSR1 superior 8 9 0.78 (0.53 - ■ 1.00) 0.82 (0.63 - ■ 1.00) CHI3L1 PI3 MSR1 lower 8 9 0.68 (0.40 - ■ 0.96) 0.82 (0.62 - ■ 1.00)
[0296] CHI3L1 Periostin upper MSR1 8 10 0.80 (0.57 - ■ 1.00) 0.88 (0.72 - ■ 1.00) CHI3L1 Periostin lower MSR1 8 10 0.80 (0.57 - ■ 1.00) 0.89 (0.73 - ■ 1.00) CHI3L1 upper MSR1 lower MSR1 8 10 0.68 (0.41 - ■ 0.94) 0.76 (0.54 - 0.98) IL10 PI3 Periostina 6 5 0.77 ■ 1.00) 0.97 (0.89 - ■ 1.00) IL8 PI3 Periostina 7 7 (0.58 - ■ 1.00)
[0297] PI3 Periostin upper MSR1 8 9 (0.30 - 0.89) 0.72 (0.48 - 0.97) PI3 Periostin lower MSR1 8 9 0.60 (0.30 - 0.89) 0.82 (0.61 - ■ 1.00) PI3 Periostin SERPINB2 6 5 0.93 (0.78 - ■ 1.00)
[0298] PI3 Upper MSR1 Lower MSR1 8 9 0.60 (0.30 - 0.89) 0.78 (0.52 - ■ 1.00) Periostin Upper MSR1 MSR1
[0299] lower 8 10 0.62 (0.35 - 0.90) 0.81 (0.61 - ■ 1.00)
[0300]
[0301] Based on the information presented in Tables 14 to 16, we propose as the seventh aspect of the invention, an in vitro method to select subjects at risk of suffering from non-allergic asthma with mild / moderate or severe persistence, comprising: (a) measuring the standard or concentration level of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level, where concentration differences of at least one of said protein biomarkers is indicative of that said subject presents a risk of suffering non-allergic asthma with different levels of severity depending on the type of biomarker and its level of differential expression (in terms of concentration levels). It is noted that said concentration differences with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 14 clearly indicates when the overexpression or under-expression of each of the biomarkers is indicative that said subject is at risk of suffering from non-allergic asthma with different levels of persistence. On the other hand, Tables 15 and 16 indicate specific combinations of biomarkers useful in determining the risk of suffering from non-allergic asthma with different levels of persistence. Each of said combinations is part and can be implemented in the method proposed in the seventh aspect of the invention.
[0302]
[0303] A preferred embodiment of the seventh aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having non-allergic asthma with different levels of persistence, comprising steps a) and b) of the seventh aspect of the invention, and optionally (c) confirming the presence of non-allergic asthma with different levels of persistence by means of a clinical examination.
[0304]
[0305] Another preferred embodiment of the seventh aspect of the invention relates to an in vitro method for monitoring the response to a therapy or for monitoring the progression of non-allergic asthma, in a subject suffering from said disease, comprising steps a) and b) of the seventh aspect of the invention.
[0306]
[0307] Another preferred embodiment of the seventh aspect of the invention relates to a method of treating subjects suffering from non-allergic asthma, comprising steps a) and b) of the fifth aspect of the invention, and (c) treating the patient who has been treated. diagnosed non-allergic asthma, taking into account the type of severity or persistence that it presents. It is noted that possible therapies are expressly mentioned throughout the description, in particular in the first aspect of the invention.
[0308]
[0309] Another preferred embodiment of the seventh aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of samples provided in the first aspect of the invention.
[0310]
[0311] Additionally and again, based on the information set forth in Tables 14 to 16, we propose as an eighth aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the seventh aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is indicative of the risk of having non-allergic asthma with different levels of persistence, to diagnose in vitro the risk of having non-allergic asthma with a certain persistence, be it mild / moderate or severe.
[0312]
[0313] A preferred embodiment of the eighth aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0314]
[0315] BIOMARKERS FOR ALLERGIC ASTHMA (AA)
[0316]
[0317] 1. Comparisons between Controls and Allergic Asthmatics (AA) (Total population)
[0318] - N0 = Group observations Control
[0319] - N1 = Observations in Allergic Asthmatic Group
[0320] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0321]
[0322] Table 17. Individual ROC curves
[0323] Variable N0 N1 AUC (95% CI) Threshold
[0324] CHI3L1 30 30 0.78 (0.66 -0.91) 20065
[0325] IL10 9 21 0.37 (0.14 -0.60) 101.4
[0326] IL8 9 14 0.76 (0.56 - 0.97) 64
[0327] PI3 30 30 0.44 (0.29 - 0.59) 8196
[0328] Periostin 30 30 0.51 (0.36 - 0.66) 13544
[0329] PHLDA1 8 6 0.50 (0.16 -0.84) 0.005
[0330] SERPINB2 6 11 0.97 (0.90 - 1.00) 0.375
[0331] Table 18. ROC curves for models with combinations of two variables Variables Variables Combination N0 N1 quantitative qualitative
[0332] CHI3L1 Periostin 30 30 0.79 (0.66 - 0.91) 0.80 (0.69 - 0.91)
[0333] IL10 Periostin 9 21 0.85 (0.69 - 1.00) 0.85 (0.73 - 0.98)
[0334] IL8 Periostin 9 14 0.74 (0.52 - 0.95) 0.77 (0.58 - 0.95) PI3 + Periostin 30 30 0.56 (0.41 - 0.71) 0.60 (0.46 - 0.73)
[0335] Periostin PHLDA1 8 6 0.79 (0.51 - 1.00) 0.90 (0.76 - 1.00) Periostin SERPINB2 6 11 0.95 (0.85 - 1.00) 0.98 (0.93 -1.00)
[0336]
[0337] Table 19. ROC curves for models with combinations of three variables
[0338] Variables Variables Variable N0 N1 quantitative qualitative
[0339] CHI3L1 IL10 Periostin 9 21 0.83 (0.64 - 1.00) 0.90 (0.80 - 1.00)
[0340] CHI3L1 IL8 Periostin 9 14 0.91 (0.79 - 1.00) 0.92 (0.82 - 1.00) CHI3L1 PI3 Periostin 30 30 0.78 (0.66 - 0.91) 0.81 (0.70 - 0.92)
[0341] CHI3L1 Periostina PHLDA1 8 6 0.71 (0.40 - 1.00) 0.93 (0.80 - 1.00) CHI3L1 Periostina SERPINB2 6 11 0.99 (0.97 -1.00) IL10 PI3 Periostina 9 21 0.86 (0.72 - 1.00) 0.86 (0.74 - 0.99) IL8 PI3 Periostina 9 14 0.67 (0.40 - 0.93) 0.87 (0.73 - 1.00) PI3 Periostin PHLDA1 8 6 0.79 (0.51 - 1.00) 0.95 (0.84 - 1.00) PI3 Periostin SERPINB2 6 11 0.97 (0.90 - 1.00) 0.99 (0.97 -1.00)
[0342]
[0343] Based on the information presented in Tables 17 to 19, we propose as an ninth aspect of the invention, an in vitro method to select subjects at risk of suffering from asthma allergic comprising: (a) measuring the pattern or concentration level of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level or with the concentration level of a healthy subject, where differences in concentration of at least one of said protein biomarkers is indicative that said subject is at risk of allergic asthma. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 17 clearly indicates when the overexpression or under-expression of each of the biomarkers is indicative that said subject is at risk of allergic asthma. On the other hand, Tables 18 and 19 indicate specific combinations of biomarkers useful in determining the risk of suffering from allergic asthma. Each of said combinations is part and can be implemented in the method proposed in the ninth aspect of the invention.
[0344]
[0345] A preferred embodiment of the ninth aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having allergic asthma, comprising steps a) and b) of the ninth aspect of the invention, and optionally (c) confirm the presence of allergic asthma by means of a clinical examination.
[0346]
[0347] Another preferred embodiment of the ninth aspect of the invention relates to an in vitro method for monitoring response to therapy or for monitoring progression of allergic asthma, in a subject suffering from said disease, comprising steps a) and b) of ninth aspect of the invention.
[0348]
[0349] Another preferred embodiment of the ninth aspect of the invention relates to a method of treating subjects suffering from allergic asthma, comprising steps a) and b) of the ninth aspect of the invention, and (c) treating the patient who has been diagnosed Allergic asthma. It is noted that possible therapies are expressly mentioned throughout the description, in particular in Tables 3 and 4, in the first aspect of the invention and directing the therapy towards the underlying allergy that is the cause of asthma (for example with Specific allergen immunotherapy or vaccines with allergens causing allergies or allergen sensitization, etc.).
[0350] Another preferred embodiment of the ninth aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of samples provided in the first aspect of the invention.
[0351]
[0352] Additionally, and again, as a result of the information presented in Tables 17 to 19, we propose as a tenth aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the ninth aspect of the invention, where the overexpression or differences in expression of at least one of the mentioned biomarkers is indicative of risk of having allergic asthma, to diagnose in vitro the risk of having allergic asthma.
[0353]
[0354] A preferred embodiment of the tenth aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0355]
[0356] 2. Comparisons between controls and mild or moderate allergic asthmatics (AA)
[0357]
[0358] N0 = Group observations Control
[0359] N1 = Observations in Group AA mild / moderate
[0360] AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0361] Table 20. Individual ROC curves
[0362] Variable N0 N1 AUC (95% CI) Threshold
[0363] CHI3L1 30 15 0.78 (0.64 -0.91) 14426
[0364] IL10 9 13 0.36 (0.11 - 0.61) 101.4
[0365] IL8 9 7 0.59 (0.24 - 0.93) 121
[0366] PI3 30 15 0.46 (0.28 - 0.64) 6519
[0367] Periostin 30 15 0.52 (0.34 - 0.69) 7067
[0368] PHLDA1 8 3
[0369] SERPINB2 6 6 1.00 (1.00 - 1.00) 0.097
[0370]
[0371] Table 21. ROC curves for models with combinations of two variables.
[0372] Variables Variables Combination N0 N1 quantitative qualitative
[0373] CHI3L1 Periostin 30 15 0.78 (0.64 -0.91) 0.78 (0.69 - 0.87)
[0374] IL10 Periostina 9 13 0.83 (0.66 - 1.00) 0.82 (0.65 - 0.98)
[0375] IL8 Periostin 9 7 0.54 (0.17 -0.91) 0.75 (0.52 - 0.99) PI3 + Periostin 30 15 0.53 (0.35 -0.71) 0.64 (0.50 - 0.79)
[0376]
[0377] Table 22. ROC curves for models with combinations of three variables Variables Variables Variable N0 N1 quantitative qualitative
[0378] CHI3L1 IL10 Periostin 9 13 0.82 (0.64 - 1.00) 0.88 (0.75 - 1.00)
[0379] CHI3L1 IL8 Periostina 9 7 0.86 (0.66 - 1.00) 0.95 (0.86 - 1.00) CHI3L1 PI3 Periostina 30 15 0.78 (0.65 - 0.92) 0.83 (0.72 - 0.94) IL10 PI3 Periostina 9 13 0.85 (0.68 - 1.00) 0.83 (0.67 - 1.00 ) IL8 PI3 Periostin 9 7 0.65 (0.36 - 0.94) 0.82 (0.59 - 1.00) Based on the information presented in Tables 20 to 22, we propose as an eleventh aspect of the invention, an in vitro method to select subjects at risk of suffering allergic asthma with mild or moderate persistence comprising: (a) measuring the pattern or concentration level of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin , obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level or with the concentration level of a healthy subject, where differences in concentration of at least one of said protein biomarkers is indicative that said subject is at risk of allergic asthma with mild or moderate persistence. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 20 clearly indicates when the overexpression or underexpression of each of the biomarkers is indicative that said subject is at risk of suffering from allergic asthma with mild or moderate persistence. On the other hand, Tables 21 and 22 indicate specific combinations of biomarkers useful in determining the risk of suffering from allergic asthma with mild or moderate persistence. Each of said combinations is part and can be implemented in the method proposed in the eleventh aspect of the invention.
[0380]
[0381] A preferred embodiment of the eleventh aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having mild or moderate persistent allergic asthma, comprising steps a) and b) of the eleventh aspect of the invention, and optionally (c) confirm the presence of allergic asthma with mild or moderate persistence by means of a clinical examination.
[0382]
[0383] Another preferred embodiment of the eleventh aspect of the invention relates to an in vitro method for monitoring response to therapy or for monitoring progression of allergic asthma with mild or moderate persistence, in a subject suffering from said disease, comprising the steps a) and b) of the eleventh aspect of the invention.
[0384]
[0385] Another preferred embodiment of the eleventh aspect of the invention relates to a method of treating subjects suffering from allergic asthma with mild or moderate persistence, comprising steps a) and b) of the eleventh aspect of the invention, and (c) treating the patient by You have been diagnosed with allergic asthma with mild or moderate persistence. It is noted that possible therapies are expressly mentioned throughout the description, particularly in the ninth aspect of the invention.
[0386] Another preferred embodiment of the eleventh aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of biological samples provided in the first aspect of the invention.
[0387]
[0388] Additionally, and again, based on the information set forth in Tables 20 to 22, we propose as the twelfth aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the eleventh aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is indicative of the risk of having allergic asthma with mild or moderate persistence, to diagnose in vitro the risk of having allergic asthma with mild persistence or moderate.
[0389]
[0390] A preferred embodiment of the twelfth aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0391]
[0392] 3. Comparisons Between Controls and Severe Allergic Asthmatics (AA)
[0393]
[0394] - N0 = Group observations Control
[0395] - N1 = Observations in Group AA severe
[0396] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0397] Table 23. ROC curves
[0398] Variable N0 N1 AUC (95% CI) Threshold
[0399] CHI3L1 30 15 0.72 (0.57 - 0.87) 20202
[0400] IL10 11 13 0.45 (0.20 - 0.69) 457.4
[0401] IL8 14 7 0.52 (0.22 - 0.82) 122
[0402] PI3 29 15 0.46 (0.28 - 0.64) 3269
[0403] Periostin 30 15 0.62 (0.45 - 0.79) 22785
[0404] Upper msr1
[0405] Lower MSR1
[0406] PHLDA1 8 3
[0407] SERPINB2 11 6 0.77 (0.54 - 1.00) 0.086
[0408]
[0409] Table 24. ROC curves for models with combinations of two variables
[0410] Variables Variables Combination N0 N1 qualitative quantitative CHI3L1 IL10 9 8 0.60 (0.31 - 0.89) 0.80 (0.61 - 0.99) CHI3L1 IL8 9 7 1.00 (1.00 - 1.00) 0.99 (0.97 - 1.00) CHI3L1 PI3 30 15 0.80 (0.67 - 0.93) 0.83 (0.73 - 0.94) CHI3L1 Periostina 30 15 0.80 (0.67 - 0.92) 0.86 (0.75 - 0.96) IL10 PI3 9 8 0.62 (0.33 - 0.92) 0.82 (0.60 - 1.00) IL10 Periostina 9 8 0.86 (0.68 - 1.00) 0.98 (0.93 - 1.00) IL8 PI3 9 7 0.95 (0.85 - 1.00) 0.94 (0.85 - 1.00) IL8 Periostina 9 7 0.95 (0.85 - 1.00) 0.94 (0.85 - 1.00) PI3 + Periostina 30 15 0.58 (0.40 - 0.76) 0.68 (0.54 - 0.81) PI3 SERPINB2 6 5 0.93 (0.78 - 1.00) 0.97 (0.89 - 1.00) Periostin SERPINB2 6 5 0.97 (0.87 - 1.00) 0.98 (0.94 - 1.00) Table 25. ROC curves for models with combinations of three variables
[0411] Variables Variables Variable N0 N1 quantitative qualitative
[0412] CHI3L1 IL10 Periostina 9 8 0.86 (0.68 - 1.00) 0.99 (0.95 - 1.00) CHI3L1 PI3 Periostina 30 15 0.81 (0.68 - 0.94) 0.88 (0.79 - 0.98) IL10 PI3 Periostina 9 8 0.89 (0.73 - 1.00) 0.99 (0.95 - 1.00 ) IL8 PI3 Periostin 9 7 0.94 (0.82 - 1.00) 0.99 (0.97 - 1.00)
[0413]
[0414] Based on the information set forth in Tables 23 to 25, we propose as the 13th aspect of the invention, an in vitro method to select subjects at risk of suffering severe allergic asthma that includes: (a) measuring the pattern or level of concentration of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level or with the concentration level of a healthy subject, where differences in concentration of at least one of said protein biomarkers is indicative that said subject is at risk of suffering severe allergic asthma. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 23 clearly indicates when the overexpression or underexpression of each of the biomarkers is indicative that said subject is at risk of suffering allergic asthma with severe persistence. On the other hand, Tables 24 and 25 indicate specific combinations of biomarkers useful in determining the risk of suffering severe allergic asthma. Each of said combinations is part and can be implemented in the method proposed in the 13th aspect of the invention.
[0415]
[0416] A preferred embodiment of the 13th aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having severe persistent allergic asthma, comprising steps a) and b) of the 13th aspect of the invention, and optionally (c) confirming the presence of severe persistent allergic asthma by means of a clinical examination.
[0417] Another preferred embodiment of the 13th aspect of the invention relates to an in vitro method to monitor response to therapy or to monitor progression of allergic asthma with severe persistence, in a subject suffering from said disease, comprising steps a) and b) of the 13th aspect of the invention.
[0418]
[0419] Another preferred embodiment of the 13th aspect of the invention relates to a method of treating subjects suffering from severe persistent allergic asthma, comprising steps a) and b) of the 13th aspect of the invention, and (c) treating the patient by you have been diagnosed with non-allergic asthma with severe persistence. It is noted that possible therapies are expressly mentioned throughout the description, particularly in the ninth aspect of the invention.
[0420]
[0421] Another preferred embodiment of the 13th aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of biological samples provided in the first aspect of the invention.
[0422]
[0423] Additionally, and again, based on the information set forth in Tables 23 to 25, we propose as a 14th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 13th aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is indicative of the risk of having severe persistent allergic asthma, to diagnose in vitro the risk of having severe persistent allergic asthma .
[0424]
[0425] A preferred embodiment of the 14th aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0426]
[0427] 4. Comparisons between mild or moderate and severe Allergic Asthmatics (AA)
[0428]
[0429] - N0 = Observations in group AA Mild / mod
[0430] - N1 = Observations in Group AA Serious
[0431] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0432] Table 26. Individual ROC curves
[0433] Variable N0 N1 AUC (95% CI) Threshold
[0434] CHI3L1 15 15 0.50 (0.27 - 0.72) 24144
[0435] IL10 13 8 0.46 (0.20 - 0.72) 57.1
[0436] IL8 7 7 0.82 (0.58 - 1.00) 17
[0437] PI3 15 15 0.56 (0.35 - 0.78) 5524
[0438] Periostin 15 15 0.52 (0.30 - 0.74) 19119
[0439] Upper msr1
[0440] Lower MSR1
[0441] PHLDA1 3 3
[0442] SERPINB2 6 5 0.77 (0.44 - 1.00) 0.095
[0443]
[0444] Table 27. ROC curves for models with combinations of two variables Variables Variables Combination N0 N1 quantitative qualitative
[0445] CHI3L1 + Periostin 15 15 0.50 (0.28 - 0.72) 0.72 (0.55 - 0.89)
[0446] IL10 + Periostin 13 8 0.62 (0.37 - 0.88) 0.73 (0.55 - 0.90)
[0447] IL8 + Periostin 7 7 0.84 (0.62 - 1.00) 0.85 (0.69 - 1.00) PI3 + Periostin 15 15 0.54 (0.32 - 0.75) 0.66 (0.48 - 0.84)
[0448] Periostin + SERPINB2 6 5 0.93 (0.78 - 1.00) 0.90 (0.75 - 1.00) Table 28. ROC curves for models with combinations of three variables
[0449] Variables Variables Combination N0 N1 quantitative qualitative
[0450] CHI3L1 IL10 Periostin 13 8 0.63 (0.38 - 0.88) 0.83 (0.67 - 1.00)
[0451] CHI3L1 IL8 Periostin 7 7 0.84 (0.62 - 1.00) 0.92 (0.78 - 1.00) CHI3L1 PI3 Periostin 15 15 0.56 (0.35 - 0.78) 0.76 (0.58 - 0.93)
[0452] CHI3L1 Periostin
[0453]
[0454] IL10 PI3 Periostina 13 8 0.74 (0.51 - 0.97) 0.82 (0.65 - 1.00) IL8 PI3 Periostina 7 7 0.82 (0.55 - 1.00) 0.97 (0.90 - 1.00) PI3 Periostina SERPINB2 6 5 0.93 (0.78 - 1.00) 0.95 (0.84 - 1.00 )
[0455]
[0456] Based on the information presented in Tables 26 to 28, we propose as the 15th aspect of the invention, an in vitro method to select subjects at risk of suffering from allergic asthma with mild / moderate or severe persistence, comprising: (a) measuring the standard or concentration level of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an already established pattern or concentration level, where concentration differences of at least one of said protein biomarkers is indicative of that said subject is at risk of allergic asthma with different levels of severity depending on the type of biomarker and its level of differential expression (in terms of concentration levels). It should be noted that said concentration differences with respect to the reference value will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 26 clearly indicates when the overexpression or under-expression of each of the biomarkers is indicative that said subject is at risk of allergic asthma with different levels of persistence. On the other hand, Tables 27 and 28 indicate specific combinations of biomarkers useful in determining the risk of suffering from allergic asthma with different levels of persistence. Each of these combinations it is part of and can be implemented in the method proposed in the 15th aspect of the invention.
[0457]
[0458] A preferred embodiment of the 15th aspect of the invention refers to an in vitro method for the diagnosis / prognosis of a subject suspected of having allergic asthma with different levels of persistence, comprising steps a) and b) of 15 ° aspect of the invention, and optionally (c) confirm the presence of allergic asthma with different levels of persistence by means of a clinical examination.
[0459]
[0460] Another preferred embodiment of the 15th aspect of the invention refers to an in vitro method to monitor the response to a therapy or to monitor the progression of allergic asthma, in a subject suffering from said disease, comprising steps a) and b) of the 15th aspect of the invention.
[0461]
[0462] Another preferred embodiment of the 15th aspect of the invention relates to a method of treating subjects suffering from allergic asthma, comprising steps a) and b) of the 15th aspect of the invention, and (c) treating the patient who is being treated. You have diagnosed allergic asthma, taking into account the type of severity or persistence that it presents. It is noted that possible therapies are expressly mentioned throughout the description, particularly in the ninth aspect of the invention.
[0463]
[0464] Another preferred embodiment of the 15th aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group of biological samples provided in the first aspect of the invention.
[0465]
[0466] Additionally, and again, based on the information set forth in Tables 26 to 28, we propose as a 16th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 15th aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is indicative of the risk of having allergic asthma with different levels of persistence, to diagnose in vitro the risk of having allergic asthma with a certain persistence, be it mild / moderate or severe.
[0467] A preferred embodiment of the 16th aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0468]
[0469] BIOMARKERS FOR ALLERGY ( A) WITHOUT ASTHMA
[0470]
[0471] 1. Comparisons between Controls and Allergy (Total population) (A)
[0472]
[0473] - N0 = Group observations Control
[0474] - N1 = Observations in Allergic Group
[0475] - AUC: Area Under the ROC Curve. For models with combinations of two or more variables, the AUC value has been divided into two values: Quantitative AUC value named in the tables as "Quantitative variables" and Qualitative AUC value named in the tables as "Qualitative variables".
[0476]
[0477] Table 29. Individual ROC curves
[0478] Variable N0 N1 AUC (95% CI) Threshold
[0479] CHI3L1 30 14 0.63 (0.45 - 0.82) 9953
[0480] IL10 9 4
[0481] IL8 9 7 0.78 (0.48 - 1.00) 627
[0482] PI3 30 14 0.68 (0.49 - 0.87) 7232
[0483] Periostin 30 14 0.74 (0.60 - 0.89) 14505
[0484] PHLDA1 8 7 0.48 (0.15 -0.81) 0.014
[0485] SERPINB2 6 5 0.70 (0.32 - 1.00) 0.554
[0486] Table 30. ROC curves for models with combinations of two variables
[0487] Variables Variables Combination N0 N1 quantitative qualitative
[0488] CHI3L1 Periostin 30 14 0.75 (0.61 - 0.90) 0.85 (0.76 - 0.94)
[0489] IL8 Periostin 9 7 0.90 (0.75 - 1.00) 0.95 (0.88 - 1.00) PI3 Periostin 30 14 0.80 (0.65 - 0.94) 0.90 (0.83 - 0.98)
[0490] Periostin + PHLDA1 8 7 0.39 (0.08 - 0.70) 0.70 (0.42 - 0.97) Periostin SERPINB2 6 5 0.80 (0.50 - 1.00) 0.95 (0.84 - 1.00)
[0491]
[0492] Table 31. ROC curves for models with combinations of three variables
[0493] Variables Variables Variable N0 N1 quantitative qualitative CHI3L1 PI3 Periostina 30 14 0.80 (0.66 - 0.95) 0.93 (0.87 - 1.00)
[0494] CHI3L1 Periostin PHLDA1 8 7 0.66 (0.35 - 0.97) 0.85 (0.57 - 1.00) CHI3L1 Periostin
[0495] SERPINB2 6 5 0.77 (0.46 - 1.00)
[0496] PI3 Periostin PHLDA1 8 7 0.82 (0.57 - 1.00) 0.93 (0.81 - 1.00) PI3 Periostin SERPINB2 6 5 0.90 (0.69 - 1.00)
[0497]
[0498] Following the information set forth in Tables 29 to 31, we propose, as the 17th aspect of the invention, an in vitro method for selecting allergic subjects without asthma, comprising: (a) measuring the pattern or concentration level of at least one of the following proteins: SERPINB2, lower MSR1, PHLDA1, upper MSR1, CHI3L1, IL10, IL8, PI3 and / or Periostin, obtained from a biological sample isolated from the allergic subjects to be selected; and (b) comparing said pattern or concentration level of at least one of said protein biomarkers, of the subjects to be selected with an established pattern or concentration level, where differences in concentration of at least one of said protein biomarkers is indicative that said subject has allergy but does not have asthma. It is noted that said concentration differences with respect to the healthy individual or with respect to the reference value, will correspond to an overexpression or an under expression of the concentration depending on the type of biomarker. In this sense, Table 29 clearly indicates when the overexpression or underexpression of each of the biomarkers is indicative that said subject has an allergy but does not have asthma. On the other hand, Tables 30 and 31 indicate specific combinations of biomarkers useful in determining the absence of asthma in the context of an individual with an allergy. Each of said combinations is part and can be implemented in the method proposed in the 17th aspect of the invention.
[0499]
[0500] A preferred embodiment of the 17th aspect of the invention relates to an in vitro method for diagnosing an allergic subject suspected of not having asthma, comprising steps a) and b) of the 17th aspect of the invention, and optionally (c) confirm the absence of asthma by means of a clinical examination.
[0501]
[0502] Another preferred embodiment of the 17th aspect of the invention relates to a method of treating allergic subjects who do not suffer from asthma, comprising steps a) and b) of the 17th aspect of the invention, and (c) treating the patient who is not You have been diagnosed with asthma.
[0503]
[0504] Another preferred embodiment of the 17th aspect of the invention refers to the method according to any of the preceding embodiments, where the biological sample is selected from the group detailed in the first aspect of the invention.
[0505]
[0506] Additionally, and again, based on the information set forth in Tables 29 to 31, we propose as the 18th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the first aspect of the invention, where the overexpression or differences in expression of at least one of the mentioned biomarkers is indicative that the allergic subject does not suffer from asthma.
[0507]
[0508] A preferred embodiment of the 18th aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0509] In addition to comparing with the control group, comparisons were made between the clinical groups, and based on the analysis of individual and grouped ROC curves of the 8 protein biomarkers studied (see data at the end of example 3), the best biomarker options to discriminate each analyzed clinical condition are detailed below.
[0510]
[0511] BIOMARKERS FOR DISCRIMINATION BETWEEN CLINICAL ASTHMA PHENOTYPES
[0512]
[0513] 1. Biomarkers capable of discriminating non-allergic asthmatics (ANA)
[0514] of Allergic Asthmatics (AA). Total population
[0515]
[0516] AUC CHI3L1 0.74
[0517] IL10 + Periostin 0.87
[0518] CHI3L1 + SERPINB2 0.83
[0519] CHI3L1 + IL8 0.82
[0520] IL8 + SERPINB2 0.82
[0521] PHLDA1 + SERPINB2 0.80
[0522] IL8 + Periostin 0.76
[0523] CHI3L1 + IL10 + Periostin 0.92
[0524] CHI3L1 + IL8 + Periostin 0.88
[0525] PI3 + PHLDA1 + SERPINB2 0.84
[0526] CHI3L1 + PI3 + Periostin 0.80
[0527]
[0528] Based on the information presented above, we propose as the 19th aspect of the invention, an in vitro method to discriminate between subjects at risk of suffering ANA (Non-allergic Asthmatics) from Allergic Asthmatics (AA), which comprises: (a) measuring the pattern or level of expression of at least one of the biomarkers collected above, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or level of expression of at least one of said biomarkers, of the subjects to be selected with a pattern or level of expression already established, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or a under expression of the expression depending on the type of biomarker. In this sense, the information provided throughout the present invention clearly indicates when the overexpression or under expression of each one of the biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes.
[0529]
[0530] A preferred embodiment of the 19th aspect of the invention refers to an in vitro method for the differential diagnosis between subjects at risk of suffering one of the clinical phenotypes mentioned in the previous paragraph, comprising steps a) and b) of the 19th aspect of the invention, and optionally (c) confirming the absence of allergy by means of a clinical examination.
[0531]
[0532] Another preferred embodiment of the 19th aspect of the invention relates to a method of treating subjects with a certain clinical phenotype of asthma, comprising steps a) and b) of the 19th aspect of the invention, and (c) treating the patient according to the type of asthma diagnosed. Possible treatments are reflected in the first and ninth aspects of the invention according to the clinical phenotype of the disease.
[0533]
[0534] Another preferred embodiment of the 19th aspect of the invention relates to the method according to any of the preceding embodiments, where the biological sample is selected from the group detailed in the first aspect of the invention.
[0535]
[0536] Additionally and again, based on the information set forth above, we propose as a 20th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 19th aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is capable of discriminating between subjects at risk of suffering ANA (Non-allergic Asthmatics) from Allergic Asthmatics (AA).
[0537]
[0538] A preferred embodiment of the 20th aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0539]
[0540] 2. Biomarkers capable of discriminating non-allergic asthmatics (ANA)
[0541] severe of severe Allergic Asthmatics (AA).
[0542]
[0543] AUC CHI3L1 0.82
[0544] SERPINB2 0.78
[0545] IL10 + Periostin 0.94
[0546] PI3 + SERPINB2 0.92
[0547] CHI3L1 + IL8 0.86
[0548] CHI3L1 + Periostin 0.86
[0549] IL8 + Periostin 0.86
[0550] CHI3L1 + IL8 + Periostin 0.96
[0551]
[0552] Based on the information presented above, we propose as the 21st aspect of the invention, an in vitro method to discriminate between subjects at risk of suffering severe ANA (Non-allergic Asthmatics) from severe Allergic Asthmatics (AA), comprising: (a) measuring the pattern or level of expression of at least one of the biomarkers collected above, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or level of expression of at least one of said biomarkers, of the subjects to be selected with a pattern or level of expression already established, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, the information provided throughout the present invention clearly indicates when the overexpression or under expression of each one of the biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes.
[0553]
[0554] A preferred embodiment of the 21st aspect of the invention refers to an in vitro method for the differential diagnosis between subjects at risk of suffering one of the clinical phenotypes mentioned in the paragraph above, comprising steps a) and b) of the 21st aspect of the invention, and optionally (c) confirming the absence of allergy by means of a clinical examination.
[0555]
[0556] Another preferred embodiment of the 21st aspect of the invention relates to a method of treating subjects with a determined clinical phenotype of asthma, comprising steps a) and b) of the 21st aspect of the invention, and (c) treating the patient according to the type of asthma diagnosed. Possible treatments are reflected in the first and ninth aspects of the invention according to the clinical phenotype of the disease.
[0557] Another preferred embodiment of the 21st aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group detailed in the first aspect of the invention.
[0558]
[0559] Additionally and again, based on the information set forth above, we propose as a 22nd aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 21st aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is capable of discriminating between subjects at risk of suffering severe ANA (Non-allergic Asthmatics) from severe Allergic Asthmatics (AA),
[0560]
[0561] A preferred embodiment of the 20th aspect of the invention refers to the use of the kit, where said kit can be implemented by means of any technique described in the second aspect of the invention.
[0562]
[0563] 3. Biomarkers capable of discriminating Non-allergic asthmatics (ANA) Mod / mild from Allergic Asthmatics (AA) Mod / mild.
[0564]
[0565] AUC CHI3L1 + IL8 0.86
[0566] IL10 + Periostin 0.82
[0567] IL8 + PI3 0.82
[0568] IL8 + Periostin 0.82
[0569] CHI3L1 + IL10 + Periostin 0.90
[0570] CHI3L1 + PI3 + Periostin 0.80
[0571]
[0572] Based on the information presented above, we propose as the 23rd aspect of the invention, an in vitro method to discriminate between subjects at risk of suffering ANA (Non-allergic Asthmatics) Mod / mild from Allergic Asthmatics (AA) Mod / mild, comprising : (a) measure the pattern or level of expression of at least one of the biomarkers collected above, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or level of expression of at least one of said biomarkers, of the subjects to be selected with a pattern or level of expression already established, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes. It is noticed that said differences in expression with respect to the reference value, will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, the information provided throughout the present invention clearly indicates when the overexpression or under expression of each one of the biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes.
[0573]
[0574] A preferred embodiment of the 23rd aspect of the invention refers to an in vitro method for the differential diagnosis between subjects at risk of suffering one of the clinical phenotypes mentioned in the previous paragraph, comprising steps a) and b) of the 23rd aspect of the invention, and optionally (c) confirming the absence of allergy by means of a clinical examination.
[0575]
[0576] Another preferred embodiment of the 23rd aspect of the invention relates to a method of treating subjects with a certain clinical phenotype of asthma, comprising steps a) and b) of the 23rd aspect of the invention, and (c) treating the patient according to the type of asthma diagnosed. Possible treatments are reflected in the first and ninth aspects of the invention according to the clinical phenotype of the disease.
[0577]
[0578] Another preferred embodiment of the 23rd aspect of the invention refers to the method according to any of the preceding embodiments, where the biological sample is selected from the group detailed in the first aspect of the invention.
[0579]
[0580] Additionally and again, based on the information set forth above, we propose as a 24th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 23rd aspect of the invention, where differences in the expression of at least one of the aforementioned biomarkers are able to discriminate between subjects at risk of suffering ANA (Non-allergic Asthmatics) Mod / mild from Allergic Asthmatics (AA) Mod / mild.
[0581]
[0582] 4. Biomarkers capable of discriminating Allergic Asthmatics (AA) from Allergics (A). Total population.
[0583]
[0584] AUC IL8 0.88
[0585] Periostin 0.8
[0586] SERPINB2 0.93
[0587] CHI3L1 + SERPINB2 1
[0588] PI3 + SERPINB2 0.96
[0589] CHI3L1 + IL8 0.91
[0590] CHI3L1 + Periostin 0.81
[0591] IL8 + PI3 + Periostin 0.93
[0592]
[0593] Based on the information presented above, we propose as the 25th aspect of the invention, an in vitro method to discriminate between subjects at risk of AA (Allergic Asthmatics) from Allergy sufferers (A), which comprises: (a) measuring the pattern o expression level of at least one of the biomarkers collected above, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or level of expression of at least one of said biomarkers, of the subjects to be selected with a pattern or level of expression already established, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, the information provided throughout the present invention clearly indicates when the overexpression or under expression of each one of the biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes.
[0594]
[0595] A preferred embodiment of the 25th aspect of the invention refers to an in vitro method for the differential diagnosis between subjects at risk of suffering one of the clinical phenotypes mentioned in the previous paragraph, comprising steps a) and b) of the 25th aspect of the invention, and optionally (c) confirming the absence of asthma by means of a clinical examination.
[0596]
[0597] Another preferred embodiment of the 25th aspect of the invention relates to a method of treating subjects with a determined clinical allergy phenotype, with and without asthma, comprising steps a) and b) of the 25th aspect of the invention, and (c ) treat the patient who has been diagnosed with asthma. Possible treatments are reflected in the first and ninth aspects of the invention according to the clinical phenotype of the disease.
[0598] Another preferred embodiment of the 25th aspect of the invention refers to the method according to any of the preceding embodiments, where the biological sample is selected from the group detailed in the first aspect of the invention.
[0599]
[0600] Additionally and again, based on the information set forth above, we propose as a 26th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 25th aspect of the invention, where differences in the expression of at least one of the aforementioned biomarkers are capable of discriminating between subjects at risk of AA (Allergic Asthmatics) from Allergy sufferers (A).
[0601]
[0602] 5. Biomarkers capable of discriminating Allergic Asthmatics (AA)
[0603] Allergic (A).
[0604] AUC IL8 0.80
[0605] Periostin 0.77
[0606]
[0607] IL8 + Periostin 0.90
[0608] IL8 + PI3 + Periostin 0.98
[0609]
[0610] Based on the information presented above, we propose as the 27th aspect of the invention, an in vitro method to discriminate between subjects at risk of severe AA (Allergic Asthmatics) from Allergy sufferers (A), comprising: (a) measuring the pattern or level of expression of at least one of the biomarkers collected above, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or level of expression of at least one of said biomarkers, of the subjects to be selected with a pattern or level of expression already established, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, the information provided throughout the present invention clearly indicates when the overexpression or under expression of each one of the biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes.
[0611] A preferred embodiment of the 27th aspect of the invention refers to an in vitro method for the differential diagnosis between subjects at risk of suffering one of the clinical phenotypes mentioned in the previous paragraph, comprising steps a) and b) of the 27th aspect of the invention, and optionally (c) confirming the absence of asthma by means of a clinical examination.
[0612]
[0613] Another preferred embodiment of the 27th aspect of the invention relates to a method of treating subjects with a determined clinical allergy phenotype, comprising steps a) and b) of the 27th aspect of the invention, and (c) treating the patient by you have been diagnosed with asthma. Possible treatments are reflected in the first and ninth aspects of the invention according to the clinical phenotype of the disease.
[0614]
[0615] Another preferred embodiment of the 27th aspect of the invention relates to the method according to any of the preceding embodiments, where the biological sample is selected from the group detailed in the first aspect of the invention.
[0616]
[0617] Additionally, and again, based on the information set forth above, we propose as a 28th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 27th aspect of the invention, where differences in the expression of at least one of the mentioned biomarkers is capable of discriminating between subjects at risk of severe AA (Allergic Asthmatics) from Allergic (A).
[0618] 6. Biomarkers capable of discriminating Allergic Asthmatics (AA) Mod / mild Allergy (A).
[0619] AUC IL8 0.96
[0620] Periostin 0.83
[0621] SERPINB2 0.84
[0622] PI3 + SERPINB2 0.92
[0623]
[0624] Based on the information presented above, we propose as the 29th aspect of the invention, an in vitro method to discriminate between subjects at risk of AA (Allergic Asthmatics) Moderate / mild Allergy (A), comprising: (a) measuring the pattern or level of expression of at least one of the biomarkers collected above, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or expression level of at least one of said biomarkers, of the subjects to be selected with a pattern or level of expression already established, where differences in expression of at least one of said biomarkers is indicative that said subject is at risk of suffering from one of said clinical phenotypes. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, the information provided throughout the present invention clearly indicates when the overexpression or under expression of each one of the biomarkers is indicative that said subject presents a risk of suffering one of said clinical phenotypes.
[0625]
[0626] A preferred embodiment of the 29th aspect of the invention refers to an in vitro method for the differential diagnosis between subjects at risk of suffering one of the clinical phenotypes mentioned in the previous paragraph, comprising steps a) and b) of the 29th aspect of the invention, and optionally (c) confirming the absence of asthma by means of a clinical examination.
[0627]
[0628] Another preferred embodiment of the 29th aspect of the invention relates to a method of treating subjects with a determined clinical allergy phenotype, comprising steps a) and b) of the 29th aspect of the invention, and (c) treating the patient by you have been diagnosed with asthma. Possible treatments are reflected in the first and ninth aspects of the invention according to the clinical phenotype of the disease.
[0629] Another preferred embodiment of the 29th aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group detailed in the first aspect of the invention.
[0630]
[0631] Additionally, and again, based on the information set forth above, we propose as a 30th aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 29th aspect of the invention, where differences in the expression of at least one of the aforementioned biomarkers are capable of discriminating between subjects at risk of AA (Allergic Asthmatics) Moderate / mild Allergy (A).
[0632] Table 32. Gene Biomarkers. Ranking of the 33 gene biomarkers in Allergic Asthmatics (AA) compared to healthy Controls taking into account the data from the ROC curves
[0633]
[0634]
[0635]
[0636] Based on the information presented in Table 32, we propose as the 30th aspect of the invention, an in vitro method to select subjects at risk of allergic asthma as well as to determine the severity of said asthma, such as severe asthma or moderate asthma or mild, comprising: (a) measuring the pattern or level of expression of at least one of the genes collected in Table 32, obtained from a biological sample isolated from the subjects to select; and (b) comparing said pattern or expression level of at least one of said gene biomarkers, of the subjects to be selected with an already established pattern or level of expression, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of allergic asthma, as well as an indication of the severity of allergic asthma. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, Table 32 clearly indicates when the overexpression or under expression of each of the biomarkers is indicative that said subject is at risk of allergic asthma.
[0637]
[0638] A preferred embodiment of the 30th aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having allergic asthma, as well as for the diagnosis / prognosis of the severity of said asthma, which it comprises steps a) and b) of the 30th aspect of the invention, and optionally (c) confirming the absence of asthma by means of a clinical examination.
[0639]
[0640] Another preferred embodiment of the 30th aspect of the invention relates to a method of treating allergic subjects suffering from asthma, comprising steps a) and b) of the 30th aspect of the invention, and (c) treating the patient who is being treated. have diagnosed asthma. Possible treatments are reflected in the ninth aspect of the invention.
[0641]
[0642] Another preferred embodiment of the 30th aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group detailed in the first aspect of the invention.
[0643]
[0644] Additionally, and again, based on the information set forth in Table 32, we propose as the 31st aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 30th aspect of the invention, where the overexpression or differences in expression of at least one of the mentioned biomarkers is indicative of the risk that a subject suffers from allergic asthma, to diagnose in vitro the presence of risk of having allergic asthma .
[0645] Table 33. Ranking of the 9 gene biomarkers in Non-Allergic Asthma with the data from the ROC curves compared with controls.
[0646]
[0647] Based on the information presented in Table 33, we propose as the 32nd aspect of the invention, an in vitro method to select subjects at risk of developing non-allergic asthma as well as to determine the severity of said asthma, such as severe asthma or moderate asthma or mild, comprising: (a) measuring the pattern or level of expression of at least one of the genes collected in Table 33, obtained from a biological sample isolated from the subjects to be selected; and (b) comparing said pattern or expression level of at least one of said gene biomarkers, of the subjects to be selected with an already established pattern or level of expression, where differences in expression of at least one of said biomarkers is indicative that said subject presents a risk of non-allergic asthma as well as an indication of the severity of non-allergic asthma. It is noted that said differences in expression with respect to the reference value will correspond to an overexpression or an under expression of the expression depending on the type of biomarker. In this sense, Table 33 clearly indicates when the overexpression or under-expression of each of the biomarkers is indicative that said subject is at risk of suffering from non-allergic asthma.
[0648]
[0649] A preferred embodiment of the 32nd aspect of the invention relates to an in vitro method for the diagnosis / prognosis of a subject suspected of having non-allergic asthma, as well as for the diagnosis / prognosis of the severity of said asthma, comprising steps a) and b) of the 32nd aspect of the invention, and optionally (c) confirming the absence of asthma by means of a clinical examination.
[0650]
[0651] Another preferred embodiment of the 32nd aspect of the invention relates to a method of treating subjects suffering from non-allergic asthma, comprising steps a) and b) of the 32nd aspect of the invention, and (c) treating the patient being treated. You have been diagnosed with asthma. Possible treatments are reflected in the first aspect of the invention.
[0652]
[0653] Another preferred embodiment of the 32nd aspect of the invention relates to the method according to any of the preceding embodiments, wherein the biological sample is selected from the group detailed in the first aspect of the invention.
[0654]
[0655] Additionally, and again, based on the information set forth in Table 33, we propose as a 33rd aspect of the invention, the use of a kit that includes reagents that detect biomarkers to determine a level of differential expression of at least one of the biomarkers mentioned in the 32nd aspect of the invention, where the overexpression or differences in expression of at least one of the mentioned biomarkers is indicative risk of a subject suffering from non-allergic asthma, to diagnose in vitro the presence of risk of having non-allergic asthma.
[0656]
[0657] It should be noted that the biomarkers mentioned throughout the 33 aspects of the invention would improve the classification or diagnosis of the different phenotypes studied, which will have a positive impact on delimiting and improving the specific treatment guidelines to be carried out. Additionally, in the examples of the present invention and, specifically, in the tables of results of ROC curves, the individual values of each protein marker, capable of discerning one condition from another, are detailed, according to the analyzed comparison. The threshold value is the quantitative parameter capable of differentiating one condition from another. Overall, in this invention we propose different combinations of biomarkers that would allow us to discriminate with very good sensitivity and specificity the three clinical phenotypes, as well as the severity in the case of asthmatic phenotypes. All the combinations indicated are combinations that could allow making good, very good or excellent diagnostic tests. The choice in each case, we propose to perform based on the best quantitative AUC value (which allows objectifying the data), analyzed in the largest number of cases and preferably, performed by the simplest technique, the ELISA (although the combination is not ruled out ELISA and Western), which would be performed with the patients serum as a routine clinical test. In the event that genetic biomarkers are analyzed, appropriate techniques would be used for such use, such as measuring gene expression through qRT-PCR techniques.
[0658]
[0659] Additionally, some of the cited biomarkers such as the protein biomarker PHLDA1; or the SERPINB2 protein biomarker in peripheral samples, are the first time that they are described for use as potential asthma biomarkers. For this reason, a 34th aspect of the invention relates to the use of the protein biomarker PHLDA1, or the protein biomarker SERPINB2 in peripheral samples for the detection or diagnosis of asthma in a subject, preferably in a human subject. Also, a 35th aspect of the invention relates to the use of a kit or device capable of detecting any of the protein biomarkers PHLDA1, or SERPINB2 for the detection or diagnosis of asthma in a subject, preferably in a human subject.
[0660]
[0661] It is noted that each of the aspects described throughout the present description must be interpreted by virtue of the results provided in the examples and in the figures in order to be able to specifically determine those biomarkers or combinations of biomarkers, as well as their levels with respect to certain patterns, capable of discriminating between subjects at risk of asthma, in particular distinguishing asthma severity, more particularly distinguishing between different asthma phenotypes.
[0662]
[0663] The present invention is described below by means of a series of examples, the sole purpose of which is to illustrate the present invention and in no way should it be understood that they limit it.
[0664]
[0665] Examples
[0666]
[0667] Materials and methods
[0668]
[0669] STUDY POPULATION
[0670]
[0671] The study population consisted of 104 subjects from four clinically defined groups:
[0672]
[0673] 1. Control subject, defined as non-allergic, non-asthmatic subjects and without respiratory diseases (n = 30).
[0674] 2. Allergic asthmatic subjects (n = 30).
[0675] 3. Allergic, non-asthmatic subjects (n = 14).
[0676] 4. Asthmatic, non-allergic subjects (n = 30).
[0677]
[0678] The asthmatic subjects (allergic and non-allergic) came from the CIBERES Asthma Sample Bank (CIBER for Respiratory Diseases), made up of more than 300 subjects, of which an associated clinical database is available and it is estimated that approximately one 40% have allergic asthma. The bank has PBMC (peripheral blood mononuclear cells), serum and DNA.
[0679]
[0680] Control subjects and non-asthmatic allergic subjects have been specifically selected for this Project, following the protocols established in the original Project. Specifically, all the subjects were selected and clinically diagnosed by a Specialized Allergist (specifically from Seville and Granada), through clinical history and skin tests against a battery of allergens, including olive pollen. All study participants (patients and controls) were informed and proposed to participate in the study, after which they signed an Informed Consent, previously approved by the Ethical Committee for Research (CEI) of the IIS- Fundación Jiménez Díaz. Aliquots of whole blood were collected, with and without anticoagulant, which were sent to the Immunology Department of the IIS-Fundación Jiménez Díaz, to be processed.
[0681]
[0682] Selection criteria:
[0683]
[0684] ■ Non-allergic asthmatic patients with a severe, moderate or mild diagnosis according to the criteria of the Spanish Guide to Asthma Management (GEMA), and without any allergic symptoms.
[0685] ■ Allergic asthmatic patients with a severe, moderate or mild diagnosis according to the GEMA criteria.
[0686] ■ Non-asthmatic allergic patients with allergies to airborne allergens.
[0687] ■ Not having received treatment before or during sample collection
[0688] ■ Maximum availability of serum and PBMC samples.
[0689]
[0690] Exclusion criteria: Be in treatment at the time of sample collection.
[0691]
[0692] Table 34 summarizes the characteristics of the study population. As can be seen, the mean age between the groups is different, with allergic asthmatic subjects being significantly older than the other groups. The non-asthmatic allergic subjects were the youngest, this difference being statistically significant with respect to the groups of control subjects and patients with non-allergic asthma. The distribution of smokers was similar between the different groups. In addition, the table reflects the severity of asthmatic patients, who in half of the cases have a diagnosis of severe asthma, while the other of moderate-mild asthma. This table also includes the total serum IgE value measured by the Immunocap method . This assessment is important, since a high total IgE value is characteristic of patients suffering from allergies. Indeed, in our population we observed that the mean of total IgE levels was significantly increased in the two groups with allergy compared to the other groups. Also included as functional lung parameters are the percentages FVC ( percentage of forced vital capacity) and FVE ¹ ( percentage of forced expiratory volume in 1 secono) whose values less than 80% are indicative of asthma disease. Thus, we see how the values of these parameters are similar between the two asthma groups studied, although if they are analyzed considering the severity of the disease, there are significant differences within the group with non-allergic asthma between severe and those of moderate and mild diagnosis (66.33 ± 16.62 vs 85.38 ± 21.03, p = 0.0127 for% FEVi; 69.93 ± 19.94 vs 94 ± 19.52, p = 0.0031 for% FVC, respectively).
[0693]
[0694] Table 34: Study Population
[0695]
[0696]
[0697]
[0698] % FVC: percentage of forced vital capacity; % FEV ¹ : percentage of forced expiratory volume in 1 second. * Statistically significant comparisons (p <0.05) between the control group and the group of patients. # Statistically significant comparisons (p <0.05) between the non-allergic asthma group and the selected group.
[0699]
[0700] COLLECTION OF SAMPLES
[0701]
[0702] The group of subjects with asthma were selected from the asthma biobank, which has samples of PBMC (stored in liquid nitrogen), serum and DNA (stored at -80 ° C). From the PBMC, RNA and total protein were extracted, according to the protocol detailed below.
[0703]
[0704] Samples from the 30 healthy subjects and 30 non-asthmatic allergic subjects were obtained from whole blood, which were processed according to the following protocol.
[0705]
[0706] 40ml of peripheral blood was drawn from each study subject: 10ml without anticoagulant (to obtain serum) and 30ml with heparin (to obtain DNA, plasma and PBMC).
[0707] The samples were processed according to the required final product and always working in laminar flow chambers:
[0708]
[0709] ■ Obtaining serum (by centrifugation under standard conditions): Five aliquots were stored at -80 ° C for each study subject, for subsequent determinations.
[0710] ■ PBMC and plasma extraction : For this, a whole blood fractionation technique was performed: the differential gradient centrifugation of Ficol ( Linfoprep ), using the protocol of the commercial company ( Comercial Rafer). Five aliquots of plasma were collected for each subject (storage at -80 ° C) and approximately ten of PBMC (6x106 cells / vial) that were frozen in freezing medium (RPMI-1640 medium 10% inactive fetal calf serum (STFi) 10% DMSO) at -80 ° C and subsequently preserved in liquid nitrogen.
[0711] ■ RNA extraction: For the differential expression study, RNA was extracted from the PBMC samples of all study subjects (n = 104), using the Trizol method ( TriReagent RNA isolation), starting from 1x106 PBMC, following the specifications of the commercial house ( Vitro). The quantification and purity of the RNA was carried out by measuring its optical density in a Nanodrop. Samples are stored at -80 ° C until use.
[0712] ■ Protein extraction : The Trizol method also obtained the protein fraction from 1x106 PBMC. Protein was quantified by the BCA method of Thermo Fisher Scientific.
[0713] GENE EXPRESSION STUDY
[0714]
[0715] To decide the genes of interest in our study, we established the following criteria:
[0716]
[0717] 1. Relevant genes by differential expression in relation to asthma and by studies of polymorphic variants (SNPs) in asthma, obtained in more than one independent study after an exhaustive bibliographic search.
[0718] 2. Genes previously defined by our group as significant through analysis of gene expression ( Aguerrí M. et al., J. Biol. Reg. Homeost. Ag. 2013 Vol.27 ( 2): 329-341.).
[0719] 3. Candidate genes of interest in cellular plasticity, inflammation and / or regulation that could have been excluded by previous criteria.
[0720]
[0721] Based on these criteria, we selected 94 genes to make a microfluidic card design.
[0722]
[0723] The preliminary study of the expression data by PCA (Principal Component Assay) shows how the expression of these 94 genes perfectly separates the subjects by groups, confirming the good selection of the genes studied and encouraging us to search for specific biomarkers depending on the clinical phenotype. in samples such as blood (Figure 1)
[0724]
[0725] 94 genes and two endogenous genes were studied in 384-well microfluidic cards ( Applied Biosystem) for the analysis of gene expression in the RNAs extracted from the 104 study subjects, by means of the quantitative real-time polymerase chain reaction (qRT- PCR).
[0726]
[0727] In qRT-PCR expression analyzes, the expression of a certain gene is evaluated in a relative way, that is, its expression is compared with that of a gene that is expressed stably or constitutively (endogenous genes). For our microfluidic plates we chose two endogenous genes usually used with PBMC: 18S and GADPH. The qRT-PCR data were analyzed with the StatMiner program , with the help of Experts from the Genomics Unit of the Cantoblanco Science Park, Madrid.
[0728]
[0729] For the expression analysis, the Ct value or threshold cycle obtained in the qRT-PCR is compared with the endogenous Ct using the expression:
[0730] ACt = Ct gene analyzed-Ct endogenous gene.
[0731]
[0732] A higher ACt value implies lower gene expression and a lower ACt determines higher gene expression. The data obtained from the microfluidic cards were analyzed by comparing the AACt (mean of the ACt of each group AACt = [ACt (experimental)] - [ACt (control)]) between the control group and the group of each clinical condition. The significance level of the differential expression was established by a relative quantification or RQ (relative quantification) <-2 or> 2 and a set value of less than 0.05 by the Benjamini-Hochberg FDR method .
[0733]
[0734] Ten genes ( CLCA1, IL17A, IL25, IL33, IL5, IL9, MUC5AC, POSTN, SERPINB4, and TCF21) were indeterminate in all samples, and 10 genes ( ADAM33, CCL17, IL13, MUC5B, MUC2, NOS2, TSLP, CCL11 , DRB1, and IL4) could not be studied because they were detected only in some conditions or the data were inconsistent.
[0735]
[0736] To define specific gene profiles related to the different clinical conditions, the gene expression of the 3 clinical groups was compared with respect to the group of healthy control subjects. After the detailed analysis of the qRT-PCR results, the results summarized in Table 35 were obtained. From the total of the genes differentially expressed in the clinical conditions compared to the healthy control group, 22 genes were common in the three clinical groups, 42 were common in the two groups of allergic subjects and one, MSR1, was common in the 2 groups of subjects with asthma (allergic and non-allergic). On the other hand, one gene, SERPINB2 was only significantly overexpressed in the group of subjects with non-allergic asthma. In contrast, ADRB1, ALOX15, CTSG, and CX3CR1 were significantly suppressed only in the group of allergic subjects with asthma. None of the genes analyzed was exclusively differentially modulated in the group of allergic subjects without asthma.
[0737] Table 35: Results of differential gene expression between the three groups of patients with respect to the control group.
[0738]
[0739]
[0740]
[0741]
[0742] In order to find genes specifically related to asthma and / or allergy, we analyzed the statistical differences in gene expression between the three clinical conditions studied. The comparison between non-allergic asthmatic subjects vs. allergic asthmatic subjects showed that 74 genes were overexpressed in the non-allergic asthma group, with the 5 genes with the greatest statistical differences being CCL5, CHI3L1, CTSG, GZMH and IL1-R2. Those with a change in expression or RQ greater than 10 were established as the most significant genes. Comparing the groups with non-allergic asthma vs subjects with allergy without asthma we found 66 differentially expressed genes, 64 overexpressed in the asthma group and only 2 genes decreased. CHI3L1 and PI3. Selecting the genes with a stricter criterion (RQ> 10), 10 genes were differentially overexpressed in the subjects with asthma: CCL5, CRTAP, GPX3, HLA-DQB1, IL-10, IL2RB, MSR1, NLRP3, PHLDA1 and SERPINB2. PI3 was the only gene repressed with this criterion. Finally, the comparison between the groups of allergic subjects with asthma vs. allergic subjects without asthma, showed that 14 genes were differentially expressed, 4 over-expressed genes ( IL-10, MSR1, PHLDA1 and SERPINB2) and 10 repressed genes ( ALOX15, CHI3L1, CPA3, CTSG, IL1R2, IL8, NKKB1Z, PI3, SVIL, and TNF) in allergic subjects with asthma. Selection with a stricter criterion (RQ> 10), showed that 4 genes were extremely decreased in subjects with allergic asthma: CHI3L1, CPA3, CTSG and PI3.
[0743]
[0744] In order to select the most differential genes in the comparison study of the groups of sick patients and the control, we established as a criterion an RQ greater than 4 or less than 0.25. Thus we reduced the genes to 9 in the group with non-allergic asthma, 33 in the group with allergic asthma and 37 in the group with non-asthmatic allergy (Table 35). By having a population of asthmatic patients with 50% with a diagnosis of severe asthma and the other 50% for moderate and mild asthma, a comparison was made of the expression of the genes that we highlight as most significant to find out if there could be any marker of severity. This is reflected in Table 36A and 36B in which it is observed that in most genes the weight of the expression falls in the group of subjects with severe asthma. For example in Table 37A, MSR1 has a 4-fold higher expression in severely diagnosed non-allergic asthmatic patients, or PHLDA1 in which the expression is duplicated. On the other hand, in the case of CPA3 it is in the moderate-mild pathology in which there is the greatest change in the differential expression. The comparison of disease severity is not so evident in the expression of these genes in the allergic asthma group (Table 36B), but we see how at least CHI3L1, CPA3, IL8 and PI3 are shared with the group with non-allergic asthma ( Table 36A).
[0745]
[0746] Table 36: List of genes with significant differential expression ( p aj. <0.05) by group of patients with respect to the control group according to the RQ criterion> 4 or <0.25.
[0747]
[0748]
[0749]
[0750]
[0751]
[0752]
[0753]
[0754]
[0755]
[0756] A) Genes with differential expression from the group with non-allergic asthma. B) Genes with differential expression from the group with allergic asthma. C) Genes with differential expression of the group with non-asthmatic allergy. In the two groups with asthma, the comparison of severe asthma and moderate-mild asthma is added. Bold genes in common with the group with nonallergic asthma are highlighted in bold in Tables 37B and 37C.
[0757]
[0758] In summary, comparisons with control subjects in clinical groups defined a group of genes associated with severity. Specifically, in the severe non-allergic asthma group, and using stricter gene expression criteria, they allowed us to define 9 genes. Analysis of the allergic asthma group showed a larger group of differential genes, even with stricter criteria, with 33 (all repressed) being the genes associated with severity.
[0759] Example 1. PROTEIN EXPRESSION STUDY
[0760]
[0761] Given the results of gene expression, we decided to study at the protein level the expression of the most relevant genes, MSR1 (which encodes the class A macrophage junk receptor), SERPINB2 (whose transcription gives rise to a member of the family of inhibitors of the serine protease) and PHLDA1 (which gives rise to a proline and histidine-rich nuclear protein) by the western blot technique and, the genes that give rise to soluble proteins IL8, IL10, CHI3L1 or chitinase3 (a glycoprotein member of the family Glycosyl hydrolase 18) and PI3 (encoding the peptidase 3 inhibitor) by ELISA, as they are easily secreted and found in serum. We also quantify POSTN or Periostin, an extracellular matrix protein induced by IL-4 and IL-13 in airway epithelium and fibroblasts and that has a role in subepithelial fibrosis and accelerates tissue infiltration of eosinophils. Although it was one of the genes that we could not assess, since its gene expression was not assessable in our samples, serum periostin has been proposed as a biomarker of Th2 asthma, which is why we decided to measure its protein expression (by ELISA).
[0762]
[0763] 1. Expression of MSR1, SERPINB2 and PHLDA1
[0764]
[0765] The analysis of the expression of these three proteins was carried out by the western blot technique . This technique separates a mixture of proteins based on their molecular weight using an acrylamide gel. The separated proteins in the gel are transferred to a membrane, giving rise to a pattern of protein bands. The membrane is incubated with enzyme-labeled antibodies specific for the protein of interest. The antibodies that bind are detected by exposure to ultraviolet light , since the enzyme bound to the antibody reacts with a substrate that we supply it. The development system used in our tests was that of ECL. The thickness of the band gives an idea of the amount of protein, so it can be standardized to obtain the amount of protein in the sample.
[0766]
[0767] The protein extract obtained from the PBMC of the study subjects was quantified using the BCA technique and we performed the electrophoresis on SDS-PAGE. 12% gels were prepared in Novex cassettes ( Life Technologies) consisting of a lower separating part (buffer of the separating gel 1M Tris-HCl pH 8.8, 50% acrylamide / bisacrylamide (29: 1), 10% SDS, 10% APS and TEMED) and another superior concentrator (0.375M Tris-HCl pH 6.8 buffer gel, 50% acrylamide / bisacrylamide (29: 1), 10% SDS, 10% APS and TEMED). Tampon Electrophoresis was also performed in the laboratory with the following protocol: 25mM Trizma base, 0.2M glycine and 0.1% SDS. The protein fraction is loaded into different wells (the amount depends on the primary antibody used), being previously denatured at 70 ° C for 10 minutes. The electrophoresis was performed at 125V for 1.5 hours. The Blot Dry Bloting system from Invitmgen ( ThermoFisherScientific) was used for the transfer of the proteins to nitrocellulose membranes. Western Breeze Chemiluminescent kit ( Invitrogen, Thermo Fisher Scientific) was used for blocking and washing the membrane and detection of the bands . After blocking the membrane (approximately 1 hour), it was incubated with the primary antibody at 4 ° C overnight with different dilutions according to the one studied, and after a series of washes, it was incubated with the secondary antibody (at room temperature). for 30 minutes). After development on the Amersham Imager 6000 ( GE Healthcare Life Sciences), the bands corresponding to each protein were obtained. After tuning these antibodies, each had its optimal dilution and adequate amount of protein load.
[0768]
[0769] For the study of MSR1, we studied the differential protein expression between the group with severe non-allergic asthma and the control group, since it is in these that a greater change in expression is observed and a greater association with severity at the level of gene expression.
[0770] Rabbit polyclonal IgG antibody specific for human CD204 (or MSR1) ( Thermo Fisher Scientific) was used for MSR1 at a dilution of 1: 2500 and loading 40 ^ g of sample. Its molecular weight (MW) is 75kDa. Two main bands were observed in its profile, one between the molecular weights 113 and 72.7 (upper band) and the other between the marker 72.7 and 46.7 (lower band). When analyzing the relative quantification of the bands of 9 control subjects and 18 severe non-allergic asthmatic patients, we saw significant differences only in the lower band that had higher expression in healthy than in asthmatic subjects (Figure 2)
[0771]
[0772] The MSR1 gene is one of the ones that we find the most differentials in asthmatic disease and we also show its importance in the severity of non-allergic asthma. The expression of the MSR1 protein in PBMC manifests with a different protein profile in healthy subjects and non-allergic asthmatic patients. These data confirm the protein expression of MSR1 in PBMC and point to interesting differences between healthy and asthmatic subjects.
[0773]
[0774] The human SERPINB2-specific rabbit polyclonal IgG antibody ( R&D Systems) was diluted 1: 1000 and 10 ^ g of sample was loaded onto the gel. Its molecular weight is 49kDa. Figure 3 represents the western blot results of SERPINB2. 6 subjects were studied control, 11 non-allergic asthmatic subjects (6 with severe asthma and 5 with moderate-mild asthma), 11 allergic asthmatic subjects (6 with severe asthma and 5 with moderate-mild asthma) and 5 subjects with non-asthmatic allergy. The relative quantification of the band of around 43kDa shows significant differences between the different groups. The control group (0.66 ± 0.31) and the group with non-asthmatic allergy (0.41 ± 0.33) statistically differ from the two groups with asthma (0.11 ± 0.05 without allergy, and 0.08 ± 0.04 with allergy), with a p <0.0001 and p <0.05, respectively.
[0775]
[0776] The human PHLDA1 specific rabbit polyclonal IgG antibody ( Invitrogen, Thermo Fisher Scientific) was diluted 1: 500 and 10 ^ g of sample was loaded (band height should be 48kDa). Figure 4 shows the western blot results of PHLDA1 from 8 control subjects, 5 non-allergic asthmatic subjects (3 with severe asthma and 2 with moderate-mild asthma), 6 allergic asthmatic subjects (3 with severe asthma and 3 with mild moderate asthma) and 7 subjects with non-asthmatic allergy. Although the non-allergic asthmatic group shows the highest mean expression of this protein, the relative quantification of the band of around 43kDa does not show significant differences between the different groups.
[0777]
[0778] 2. Protein expression of IL8, IL10, CHI3L1, PI3 and POSTN
[0779]
[0780] The study and quantification of these soluble proteins was carried out with the ELISA technique. The ELISA detection method ( Enzyme-Linked Immuno Sorbent Assay) is an immunoassay technique in which a primary antibody immobilized on a plate detects the antigen, which is recognized by a biotinylated secondary antibody, which in turn binds to it an antibody with a bound enzyme, which is capable of generating a color change detectable product by reacting with the appropriate chromogenic substrate. The intensity of the color allows indirect measurement of the antigen in the sample by spectrophotometry. With this technique we measure the amount of IL8, IL10, CHI3L1, PI3 and POSTN in the serum of our patients using the kits: human IL8 ELISA kit (detection range: 62.50-2000pg / ml) from Diaclone, human Chitinase 3- like1 DuoSet ELISA (detection range: 31.20-2000pg / ml), human Trappin-2 / Elafin ( PI3) DuoSet ELISA (detection range: 31.20-2000pg / ml) and human Periostin / OSF-2 Duoset ELISA (detection range: 62.50-4000pg / ml) from R&D systems, and human Interleukin-10 ELISA (detection range: 16-1000pg / ml) from ImmunoTools, whose color is measured at 450nm. The mean results by group and the statistical comparisons are summarized in Figure 5.
[0781] The data indicated significant differences between the levels of jL8 in the group of control subjects and allergic asthmatics, compared with that of non-asthmatic allergic patients (283.69 ± 167.69pg / ml, 207.02 ± 328.90pg / ml, 912.84 ± 608.74pg / ml, respectively. ) (Figure 5A). There were 68.97% of control subjects with negative values, 53.33% in non-allergic asthmatic patients, 56.67% in allergic asthmatic patients and 46.15% in non-asthmatic allergic patients. When performing the most detailed analysis of patients with severe diagnosis and with moderate-mild diagnosis within the group of non-allergic asthmatics and allergic asthmatics, this did not show significant differences between the IL8 concentrations of each asthmatic group (505.49 ± 387.80pg / ml subjects severe asthmatics and 377.79 ± 338.27pg / ml moderate-mild asthmatic patients; 342.91 ± 406.96pg / ml severe allergic asthmatic subjects and 48.47 ± 69.77pg / ml moderate-mild allergic asthmatic patients). We highlight that there is a tendency for more severe asthmatic patients of the two pathological conditions to have higher levels. In gene expression we obtained the opposite. This is possibly due to the release in the blood (serum) of IL8 produced by other cell types than PBMCs.
[0782]
[0783] Serum CHI3L1 concentrations also showed significant differences between the control group and allergic asthma (15729.18 ± 8576.85pg / ml and 22812.55 ± 3573.46pg / ml, respectively) (Figure 5C). Neither group presented negative values. Analyzing the patients according to severity within the groups with asthma, no significant differences were found between the CHI3L1 concentrations of each asthmatic group (17026.99 ± 4845.20pg / ml for severe asthmatic subjects and 21702.56 ± 11589.97pg / ml for moderate asthmatic patients- mild; 22708.69 ± 4301.77pg / ml severe allergic asthmatic subjects and 22916.40 ± 2814.77pg / ml moderate-mild allergic asthmatic patients).
[0784]
[0785] The mean serum levels of IL10 and PI3 did not show significant differences between any of the groups (Figure 5B and 5D). However, the analysis of IL10 according to severity in the groups of asthmatic patients, showed that although there was no statistically significant difference, subjects with severe asthma in both cases, showed increased levels of IL10 (200 ± 219vs 105.27 ± 79pg / ml in severe vs moderate-mild non-allergic asthmatics; 211.40 ± 193 vs 168 ± 136pg / ml in severe vs. moderate-mild allergic asthmatics). The gene expression results are consistent with the trend of the non-allergic asthma group.
[0786]
[0787] The mean POSTN (or Periostin) levels did show differences between the different groups (Figure 5E). The group of patients with non-asthmatic allergy (11190.29 ± 2310.13pg / ml) was the only one that showed significant differences with the control group (15487.71 ± 6532.85pg / ml). Significant differences were also observed with the two groups with asthma (18679.59 ± 8086.07pg / ml non-allergic asthma, 15199.93 ± 4263.88pg / ml allergic asthma), with the group of rhinitics having the lowest levels of POSTN. When comparing the groups with asthma, asthma without allergy had higher levels of this protein than asthma with allergy, showing significant differences. When studying these groups according to the severity of asthma, statistically significant differences were obtained between the control group and the group with severe non-allergic asthma (15487.71 ± 6532.85pg / ml and 20198.91 ± 7859.24pg / ml, respectively). Furthermore, it was observed, significantly, that severe non-allergic asthma had higher POSTN levels than severe allergic asthma (15305.71 ± 4607.65pg / ml).
[0788]
[0789] Example 2. BIOMARKER ANALYSIS BY ROC CURVES
[0790]
[0791] To emphasize the good selection of genes that we have defined as possible biomarkers and to assess their specificity and sensitivity, we performed ROC curves of gene expression in groups with asthma. We obtained a large number of genes with moderate or high significance, with an area under the curve (AUC) greater than 0.80. To interpret the ROC curves, the following intervals are established for the AUC values: 0.50-0.60 bad test, 0.61-0.75 regular test, 0.76-0.90 good test, 0.91-0.96 very good test, and 0.97-1 excellent test. This analysis has been performed on the gene and protein expression of the most differential markers in the 3 clinical study groups. Markers were studied individually and in combination with each other.
[0792]
[0793] Table 37 (A, B and C) summarizes the data obtained from the ROC curve analysis of the two groups with asthma, studying the markers at the gene and protein level individually. Most analyzes fall into the category of good or very good. At the protein level, IL10 in the total group of asthma without allergy and the moderate-mild group do not fall into any category according to our criteria. MSR1 was not assessed at the protein level in the mild-mild non-allergic asthmatic group. PHLDA1 at protein level could not be classified in any criteria since there were not enough data in asthma without allergy. In the total group of asthma with allergies and specifically the moderate-mild group, the protein expression of PI3 and IL10 did not fall into any category according to our criteria either. MSR1 was not assessed at the protein level in the allergic asthmatic group. PHLDA1 at the protein level could not be classified into the asthma groups without moderate-mild or severe allergy. Periostin only It could be classified with the total group and the moderate-mild asthma with allergy. In the group with only allergy, at the protein level MSR1 was not studied and the result of the analysis of PHLDA1 does not fall into any category of asthma.
[0794]
[0795] Table 38 summarizes the results of the combination of the analysis by ROC curves of the biomarkers according to their gene and protein expression, respectively
[0796]
[0797] Table 39 summarizes the results of the combination of three markers of the analysis by ROC curves according to their gene and protein expression.
[0798] Table 37: Classification by analysis of ROC curves of biomarkers according to their individual gene and protein expression.
[0799] A) Non-allergic asthmatic group (ANA).
[0800]
[0801] Summary of the analysis by ROC curves of the important biomarkers of the group with non-allergic asthma, indicating the markers analyzed according to the value of the ROC curve, indicating in each biomarker the comparison to which it refers. C: Control subject group. Total: total group of subjects in the group. ML: group of subjects with moderate-mild asthma. G: group of subjects with severe asthma.
[0802]
[0803] B) Asthmatic allergic group (AA).
[0804] Summary of the analysis by ROC curves of the important biomarkers of the group with allergic asthma, indicating the markers analyzed according to the value of the ROC curve, indicating in each biomarker the comparison to which it refers. C: Control subject group. Total: total group of subjects in the group. ML: group of subjects with mild moderate asthma. G: group of subjects with severe asthma.
[0805]
[0806] C) Non-asthmatic allergy group (A).
[0807]
[0808]
[0809]
[0810]
[0811] Summary of the analysis by ROC curves of the important biomarkers of the group with allergy without asthma, indicating the markers analyzed according to the value of the ROC curve, indicating in each biomarker the comparison to which it refers. C: Control subject group. Total: total group of subjects in the group.
[0812]
[0813] Table 38: AUC values of the analysis of ROC curves by combining the protein expression of two biomarkers.
[0814]
[0815] A) Total non-allergic asthmatic group (ANA) compared to the control group
[0816]
[0817]
[0818]
[0819] All values with AUC criteria> 0.75, good, very good or excellent are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and MSR1sup and minimally between CHI3L1 and MSR1inf, CHI3L1 and SERPINB2; POSTN (Periostin) and PHLDA1; POSTN and SERPINB2.
[0820] B) Moderate-mild non-allergic asthmatic group (ANA) compared to the control group
[0821]
[0822]
[0823]
[0824] All values with AUC criteria> 0.75 (good, very good or excellent) are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and MSR1sup; CHI3L1 and SERPINB2; IL8 and PI3; IL8 and POSTN (Periostin) and PHLDA1; POSTN and SERPINB2.
[0825] C) Severe non-allergic asthmatic group (ANA) compared to the control group.
[0826]
[0827]
[0828]
[0829] All values with AUC criteria> 0.75 (good, very good or excellent) are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and MSR1sup; minimally between CHI3L1 and MSR1 inf; minimally between PI3 and MSR1 inf; POSTN (Periostina) and SERPINB2.
[0830]
[0831] D) Moderate-mild non-allergic asthmatic group (ANA) compared to severe ANA group
[0832]
[0833]
[0834]
[0835] All values with AUC criteria> 0.75 (good, very good or excellent) are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and POSTN (Periostina); IL10 and POSTN; IL8 and PI3; minimally between IL8 POSTN; SERPINB2 and POSTN.
[0836]
[0837] E) Total asthmatic allergic group (AA) compared to the control group
[0838]
[0839] All values with AUC criteria> 0.75 (good, very good or excellent) are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; minimally between CHI3L1 and POSTN (Periostina); CHI3L1 and SERPINB2; IL10 and POSTN; POSTN and PHLDA1.
[0840]
[0841] F) Moderate-mild allergic asthmatic group (AA) compared to the control group
[0842]
[0843]
[0844]
[0845] All values with AUC criteria> 0.75 (good, very good or excellent) are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; IL10 and POSTN.
[0846] G) Severe allergic asthmatic group (AA) compared to the control group
[0847]
[0848]
[0849]
[0850] All values with AU C criteria> 0.75 (good, very good or excellent) are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; CHI3L1 and PI3; CHI3L1 and POSTN (Periostina); CHI3L1 and SERPINB2; IL10 and POSTN; IL8 and PI3; IL8 and POSTN; PI3 and SERPINB2; POSTN and SERPINB2.
[0851]
[0852] H) Moderate-mild allergic asthmatic group (AA) compared to severe AA group
[0853]
[0854]
[0855]
[0856] All values with AUC criteria> 0.75 (good, very good or excellent) are indicated in bold. Of these, an improvement or synergy is observed between: CHI3L1 and SERPINB2; minimally between IL8 and POSTN (Periostina); PI3 and SERPINB2; POSTN and SERPINB2.
[0857] I) Non-asthmatic allergic group (A) compared to the control group
[0858]
[0859]
[0860]
[0861] In bold are the AUC values> 0.75, whose combinations of biomarkers give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; minimally between CHI3L1 and POSTN (Periostina); IL8 and PI3; IL8 and POSTN; minimally between POSTN and SERPINB2.
[0862] Table 39: AUC values of the analysis of ROC curves by combining the protein expression of three biomarkers.
[0863]
[0864] A) Non-allergic asthmatic group (ANA) compared to the control group.
[0865]
[0866]
[0867]
[0868]
[0869] In bold are the AUC values> 0.75, whose biomarker combinations give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed in: 1. Total ANA group compared to controls between: CHI3L1 PI3 MSR1 superior; minimally between CHI3L1 PI3 MSR1 lower; minimally between CHI3L1 PI3 SERPINB2, CHI3L1 POSTN MSR1 higher; minimally between CHI3L1 POSTN MSR1 lower; CHI3L1 POSTN PHLDA1; CHI3L1 POSTN SERPINB2; PI3 POSTN MSR1 upper; minimally PI3 POSTN MSR1 lower; PI3 POSTN PHLDA1; PI3 POSTN SERPINB2. 2. In the moderate / mild ANA group compared to controls between: CHI3L1 IL8 PI3; CHI3L1 IL8 POSTN; CHI3L1 PI3 MSR1 superior; IL8 PI3 POSTN; PI3 POSTN MSR1 top; PI3 POSTN SERPINB2. 3. In the severe ANA group compared to controls between: CHI3L1 IL8 PI3; minimally between CHI3L1 PI3 MSR1 lower; PI3 POSTN MSR1 upper; PI3 POSTN MSR1 lower. Total: total group of subjects in the group. ML: group of subjects with moderate-mild asthma. G: group of subjects with severe asthma.
[0870]
[0871] C) Moderate-mild non-allergic asthmatic group (ANA) compared to severe ANA group
[0872]
[0873]
[0874]
[0875]
[0876] In bold are the AUC values> 0.75, whose biomarker combinations give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed in all of them.
[0877] D) Allergic asthmatic group (AA) compared to the control group
[0878]
[0879]
[0880]
[0881]
[0882] In bold are the AUC values> 0.75, whose biomarker combinations give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed in: 1. Total AA group compared to controls in all, except the combination CHI3L1 + PI3 + POSTN. 2. Moderate / mild AA group compared to controls in all except CHI3L1 + PI3 + POSTN combination. 3. Severe AA group compared to controls in all. Total: total group of subjects in the group. ML: group of subjects with moderate-mild asthma. G: group of subjects with severe asthma.
[0883] E) Moderate-mild allergic asthmatic group (AA) compared to severe group (AA).
[0884]
[0885]
[0886]
[0887]
[0888] In bold are the AUC values> 0.75, whose biomarker combinations give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed in all except in: CHI3L1 IL8 PI3; IL8 PI3 POSTN.
[0889] F) Non-asthmatic allergic group (A) compared to the control group.
[0890]
[0891]
[0892]
[0893]
[0894] In bold are the AUC values whose combinations of biomarkers give rise to a good, very good or excellent category test. Of these, all show improvement or synergy. Total: total group of subjects in the group.
[0895]
[0896] Example 3. Global Assessment of Protein Biomarker Results
[0897]
[0898] Based on the analysis of individual and grouped ROC curves of the 8 protein biomarkers studied, the best options for biomarkers for each condition analyzed would be:
[0899]
[0900] to. Non-allergic asthma (ANA)
[0901]
[0902] 1. Biomarkers capable of discriminating ANA (Total population) of
[0903] control subjects
[0904] AUC MSR1 lower 0.96
[0905] SERPINB2 0.91
[0906] Lower MSR1 + Upper MSR1
[0907] CHI3L1 + MSR1inf 0.97
[0908] POSTN + SERPINB2 0.95
[0909] CHI3L1 + SERPINB2 0.92
[0910] POSTN + PHLDA1 0.82
[0911] CHI3L1 + MSR1sup 0.78
[0912] PI3 + POSTN + MSR1inf 0.97
[0913] CHI3L1 + POSTN + MSR1sup 0.83
[0914] PI3 + POSTN + MSR1sup 0.77
[0915]
[0916] 2. Biomarkers capable of discriminating ANA M / L from control subjects
[0917]
[0918] AUC MSR1 lower 1
[0919] SERPINB2 0.89
[0920] CHI3L1 + SERPINB2 0.97
[0921] POSTN + SERPINB2 0.97
[0922] IL8 + POSTN 0.87
[0923] CHI3L1 + MSR1sup 0.83
[0924] POSTN + MSR1sup 0.81
[0925] IL8 + PI3 0.76
[0926] CHI3L1 + IL8 + POSTN 0.87
[0927] CHI3L1 + IL8 + PI3 0.79
[0928]
[0929] 3. Biomarkers capable of discriminating ANA Grave from control subjects
[0930]
[0931] AUC MSR1 lower 0.93
[0932] SERPINB2 0.93
[0933] Lower MSR1 + Upper MSR1
[0934] POSTN + SERPINB2 0.97
[0935] PI3 + MSR1inf 0.95
[0936] CHI3L1 + MSR1inf 0.94
[0937] CHI3L1 + MSR1sup 0.76
[0938] PI3 + POSTN + MSR1inf 0.96
[0939] CHI3L1 + PI3 + MSR1inf 0.95
[0940] CHI3L1 + IL8 + PI3 0.79
[0941] PI3 + POSTN + MSR1sup 0.77
[0942] 4. Biomarkers capable of discriminating ANA M / L from ANA Grave
[0943]
[0944] AUC IL8 0.76
[0945] POSTN + SERPINB2 0.90
[0946] IL8 + PI3 0.82
[0947] IL8 + POSTN 0.78
[0948] CHI3L1 + POSTN 0.77
[0949] POSTN + IL10 0.77
[0950] CHI3L1 + IL8 + POSTN 0.98
[0951] PI3 + POSTN + SERPINB2 0.93
[0952] CHI3L1 + IL8 + PI3 0.88
[0953] CHI3L1 + POSTN + MSR1sup 0.80
[0954] CHI3L1 + POSTN + MSR1inf 0.80
[0955] CHI3L1 + PI3 + MSR1sup 0.78
[0956]
[0957] b. Allergic asthma (AA)
[0958]
[0959] 1. Biomarkers able to discriminate AA (Total population) from control subjects
[0960]
[0961] AUC SERPINB2 0.97
[0962] CHI3L1 0.78
[0963] IL8 0.76
[0964] CHI3L1 + SERPINB2 1
[0965] CHI3L1 + IL8 0.92
[0966] IL10 + POSTN 0.85
[0967] CHI3L1 + POSTN 0.79
[0968] POSTN + PHLAD1 0.79
[0969] IL10 + POSTN + PI3 0.86
[0970]
[0971] 2. Biomarkers capable of discriminating AA M / L from control subjects
[0972] AUC
[0973] SERPINB2 1
[0974] CHI3L1 0.78
[0975] CHI3L1 + IL8 0.87
[0976] IL10 + POSTN 0.83
[0977] CHI3L1 + IL8 + PI3 0.89
[0978] IL10 + POSTN + PI3 0.85
[0979]
[0980] 3. Biomarkers capable of discriminating AA Graves from control subjects
[0981]
[0982] AUC SERPINB2 0.77
[0983] CHI3L1 + IL8 1
[0984] POSTN + SERPINB2 0.97
[0985] IL8 + PI3 0.95
[0986] IL8 + POSTN 0.95
[0987] PI3 + SERPINB2 0.93
[0988] IL10 + POSTN 0.86
[0989] CHI3L1 + PI3 0.80
[0990] CHI3L1 + POSTN 0.80
[0991] IL10 + PI3 + POSTN 0.89
[0992] CHI3L1 + PI3 + POSTN 0.81
[0993]
[0994] 4. Biomarkers capable of discriminating AA M / L from AA Grave
[0995]
[0996] AUC IL8 0.82
[0997] SERPINB2 0.77
[0998] POSTN + SERPINB2 0.93
[0999] CHI3L1 + SERPINB2 0.90
[1000] PI3 + SERPINB2 0.87
[1001] IL8 + POSTN 0.84
[1002]
[1003] c. Allergy (A) without asthma
[1004]
[1005] 1. Biomarkers able to discriminate A from control subjects
[1006] AUC
[1007] IL8 0.82
[1008] CHI3L1 + IL8 1
[1009] IL8 + POSTN 0.90
[1010] IL8 + PI3 0.87
[1011] PI3 + SERPINB2 0.83
[1012] PI3 + POSTN 0.80
[1013] POSTN + SERPINB2 0.80
[1014] PI3 + POSTN + SERPINB2 0.90
[1015] PI3 + POSTN + PHLDA1 0.82
[1016]
[1017] d. Protein expression comparisons between clinical phenotypes
[1018]
[1019] 1. Comparisons between total non-allergic asthmatics (ANA) and total allergic asthmatics (AA).
[1020] - NO: Non-allergic asthmatics (ANA)
[1021] - N1: Allergic asthmatics (AA)
[1022] - AUC: Area Under the ROC Curve.
[1023]
[1024] ROC curves
[1025] Variable N0 N1 AUC (95% CI) Threshold
[1026] CHI3L1 30 30 0.74 (0.61 - 0.88) 20202
[1027] IL10 11 21 0.45 (0.23 - 0.67) 457.4
[1028] IL8 14 14 0.68 (0.46 - 0.89) 221
[1029] PI3 29 30 0.57 (0.42 - 0.72) 5126
[1030] Periostin 30 30 0.62 (0.48 - 0.77) 22785
[1031] Upper msr1
[1032] Lower MSR1
[1033] PHLDA1 5 6 0.40 (0.00 - 0.80) 0.012
[1034] SERPINB2 11 11 0.64 (0.39 - 0.88) 0.116
[1035] ROC curves for models with combinations of two variables
[1036] Variables Variables Combination N0 N1 qualitative quantitative CHI3L1 IL10 11 21 0.73 (0.49 - 0.96) 0.81 (0.65 - 0.96) CHI3L1 + IL8 14 14 0.82 (0.64 - 0.99) 0.90 (0.79 - 1.00) CHI3L1 + PI3 29 30 0.75 (0.62 - 0.89 ) 0.84 (0.75 - 0.94) CHI3L1 + Periostina 30 30 0.76 (0.64 - 0.89) 0.87 (0.79 - 0.95) CHI3L1 + PHLDA1 5 6 0.43 (0.02 - 0.85) 0.85 (0.59 - 1.00) CHI3L1 + SERPINB2 11 11 0.83 (0.64 - 1.00) 0.88 (0.74 - 1.00) IL10 + IL8 5 11 0.71 (0.42 - 0.99) 0.85 (0.65 - 1.00) IL10 + PI3 11 21 0.46 (0.24 - 0.68) 0.60 (0.40 - 0.79) IL10 + Periostin 11 21 0.87 (0.74 - 1.00) 0.74 (0.59 - 0.89) IL8 + PI3 14 14 0.67 (0.45 - 0.89) 0.74 (0.56 - 0.92) IL8 + Periostin 14 14 0.76 (0.57 - 0.94) 0.75 (0.57 - 0.93) IL8 + SERPINB2 7 7 0.82 ( 0.58 - 1.00) 0.81 (0.56 - 1.00) PI3 + Periostina 29 30 0.67 (0.53 -0.81) 0.75 (0.63 - 0.86) PI3 + PHLDA1 5 6 0.60 (0.19 - 1.00) 0.67 (0.32 - 1.00) PI3 + SERPINB2 11 11 0.69 (0.45 - 0.92) 0.77 (0.57 - 0.96) Periostin + PHLDAI 5 6 0.70 (0.34 - 1.00) 0.83 (0.57 - 1.00) Periostin + SERPINB2 11 11 0.75 (0.52 - 0.98) 0.85 (0.70 - 1.00) PHLDA1 + SERPINB2 5 5 0.80 (0.50 - 1.00) 0.82 (0.51 - 1.00) ROC curves for models with combinations of three variables
[1037] Variables Variables Variable N0 N1 quantitative qualitative CHI3L1 IL10 IL8 5 11 0.76 (0.47 - 1.00) 0.92 (0.79 - 1.00) CHI3L1 IL10 PI3 11 21 0.71 (0.48 - 0.93) 0.82 (0.65 - 0.99) CHI3L1 IL10 Periostin 11 21 0.92 (0.81 - 1.00) 0.90 (0.80 - 1.00) CHI3L1 IL8 PI3 14 14 0.82 (0.64 - 0.99) 0.93 (0.84 - 1.00) CHI3L1 IL8 Periostina 14 14 0.88 (0.76 - 1.00) 0.92 (0.82 - 1.00) CHI3L1 PI3 Periostina 29 30 0.80 (0.68 -0.91) 0.93 (0.87 - 0.99) CHI3L1 PI3 PHLDA1 5 6 0.63 (0.25 - 1.00) 0.87 (0.60 - 1.00) CHI3L1 PI3 SERPINB2 11 11 0.84 (0.65 - 1.00) 0.92 (0.78 - 1.00) CHI3L1 Periostin PHLDA1 5 6 0.77 ( 0.46 - 1.00) 0.98 (0.94 - 1.00) CHI3L1 Periostin SERPINB2 11 11 0.85 (0.69 - 1.00) 0.96 (0.89 - 1.00) CHI3L1 PHLDA1 SERPINB2 5 5 0.84 (0.52 - 1.00) 0.90 (0.70 - 1.00) IL10 IL8 PI3 5 11 ( 0.57 - 1.00) 0.95 (0.85 - 1.00) IL10 IL8 Periostin 5 11 0.87 (0.69 - 1.00) (0.70 - 1.00) IL10 PI3 Periostina 11 21 0.87 (0.74 - 0.99) 0.77 (0.58 - 0.95) IL8 PI3 Periostina 14 14 0.76 ( 0.58 - 0.94) 0.78 (0.60 - 0.96) IL8 PI3 SERPINB2 7 7 0.80 (0.54 - 1.00) (0.70 - 1.00) IL8 Periostina SERPINB2 7 7 0.82 (0.56 - 1.00) 0.87 (0.65 - 1.00) PI3 Periostina PHLDA1 5 6 0.67 (0.30 - 1.00) 0.92 (0.76 - 1.00) PI3 Periostin SERPINB2 11 11 0.77 (0.56 - 0.98) 0.89 (0.75 - 1.00) PI3 PHLDA1 SERPINB2 5 5 (0.57 - 1.00) 0.92 (0.74 - 1.00) Comparison chart. Total non-allergic asthmatic group (ANA) compared to the total allergic asthmatic group (AA)
[1038]
[1039]
[1040]
[1041] All values with AU C criteria> 0.75, good, very good or excellent are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; CHI3L1 and SERPINB2; IL10 and POSTN (Periostin), IL8 and POSTN; IL8 and SERPINB2; SERPINB2 and PHLDA1 and minimally between CHI3L1 and POSTN.
[1042] 2. Comparisons between severe non-allergic asthma (ANA) and severe allergic asthma (AA)
[1043]
[1044] - NO: Severe non-allergic asthmatics (ANA)
[1045] - N1: Severe allergic asthmatics (AA)
[1046] - AUC: Area Under the ROC Curve
[1047]
[1048] ROC curves
[1049] Variable N0 N1 AUC (95% CI) Threshold
[1050] CHI3L1 15 15 0.82 (0.67 - 0.98) 20202
[1051] IL10 6 13 0.49 (0.17 -0.81) 184.6
[1052] IL8 7 7 0.63 (0.30 - 0.97) 122
[1053] PI3 15 15 0.48 (0.26 - 0.70) 5758
[1054] Periostin 15 15 0.69 (0.50 - 0.89) 22785
[1055] Upper msr1
[1056] Lower MSR1
[1057] PHLDA1 3 3
[1058] SERPINB2 6 6 0.78 (0.47 - 1.00) 0.11
[1059]
[1060] ROC curves for models with combinations of two variables
[1061] Variables Variables Combination N0 N1 qualitative quantitative CHI3L1 + IL10 6 13 0.69 (0.39 - 0.99) 0.81 (0.54 - 1.00) CHI3L1 + IL8 7 7 0.86 (0.64 - 1.00) 0.94 (0.83 - 1.00) CHI3L1 + PI3 15 15 0.83 (0.67 - 0.98) 0.81 (0.65 - 0.97) CHI3L1 + Periostin 15 15 0.86 (0.72 - 1.00) 0.87 (0.76 - 0.99) IL10 + PI3 6 13 0.68 (0.40 - 0.96) 0.72 (0.51 - 0.94) IL10 + Periostin 6 13 0.94 (0.83 - 1.00) 0.91 (0.79 - 1.00) IL8 + PI3 7 7 0.69 (0.40 - 0.99) 0.71 (0.44 - 0.99) IL8 + Periostin 7 7 0.86 (0.65 - 1.00) 0.83 (0.62 - 1.00) PI3 + Periostin 15 15 0.69 ( 0.49 - 0.89) 0.73 (0.55 - 0.90) PI3 + SERPINB2 6 6 0.92 (0.76 - 1.00) 0.97 (0.91 - 1.00)
[1062] ROC curves for models with combinations of three variables
[1063] Variables Variables Variable N0 N1 quantitative qualitative
[1064] CHI3L1 IL8 Periostina 7 7 0.96 (0.86 - 1.00) 0.95 (0.85 - 1.00) CHI3L1 PI3 Periostina 15 15 0.86 (0.72 - 1.00) 0.87 (0.74 - 1.00) IL10 PI3 Periostina 6 13 0.94 (0.83 - 1.00) 0.92 (0.78 - 1.00 ) IL8 PI3 Periostin 7 7 0.86 (0.65 - 1.00) 0.85 (0.63 - 1.00)
[1065]
[1066] Comparison chart. Severe non-allergic asthma group (ANA) compared to severe allergic asthma group (AA)
[1067]
[1068]
[1069]
[1070] All values with AU C criteria> 0.75, good, very good or excellent are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; CHI3L1 and POSTN; IL10 and POSTN (Periostin), IL8 and POSTN; PI3 and SERPINB2 and minimally between CHI3L1 and PI3.
[1071] Comparisons between mild non-allergic asthma (ANA) and mild allergic asthma (AA)
[1072]
[1073] to. NO: Mild non-allergic asthmatics
[1074] b. N1: Mild allergic asthmatics
[1075] c. AUC: Area Under the ROC Curve
[1076] ROC curves
[1077] Variable N0 N1 AUC (95% CI) Threshold
[1078] CHI3L1 15 15 0.66 (0.43 - 0.89) 20227
[1079] IL10 5 8 0.60 (0.26 - 0.94) 167.9
[1080] IL8 7 7 0.73 (0.44 - 1.00) 221
[1081] PI3 14 15 0.62 (0.41 - 0.83) 5028
[1082] Periostin 15 15 0.53 (0.32 - 0.75) 24658
[1083] Upper msr1
[1084] Lower MSR1
[1085] PHLDA1 2 3
[1086] SERPINB2 5 5 0.60 (0.19 - 1.00) 0.134
[1087]
[1088] ROC curves for models with combinations of two variables
[1089] Variables Variables Combination N0 N1 qualitative quantitative CHI3L1 + IL10 5 8 0.60 (0.26 - 0.94) 0.75 (0.45 - 1.00) CHI3L1 + IL8 7 7 0.80 (0.51 - 1.00) 0.93 (0.79 - 1.00) CHI3L1 + PI3 14 15 0.63 (0.41 - 0.86) 0.86 (0.73 - 0.99) CHI3L1 + Periostina 15 15 0.72 (0.52 - 0.91) 0.87 (0.75 - 0.99) CHI3L1 + SERPINB2 5 5 0.72 (0.37 - 1.00) 0.88 (0.71 - 1.00) IL10 + PI3 5 8 0.68 (0.36 - 0.99) 0.70 (0.40 - 1.00) IL10 + Periostin 5 8 0.82 (0.59 - 1.00) 0.83 (0.62 - 1.00) IL8 + PI3 7 7 0.82 (0.53 - 1.00) 0.85 (0.65 - 1.00) IL8 + Periostin 7 7 0.82 ( 0.58 - 1.00) 0.84 (0.68 - 1.00) PI3 + Periostin 14 15 0.67 (0.46 - 0.87) 0.74 (0.57 -0.91) PI3 + SERPINB2 5 5 0.68 (0.30 - 1.00) 0.72 (0.40 - 1.00) Periostin + SERPINB2 5 5 0.40 (0.00 -0.81) 0.84 (0.59 - 1.00) ROC curves for models with combinations of three variables
[1090] Variables Variables Variable N0 N1 quantitative qualitative
[1091]
[1092]
[1093]
[1094]
[1095] Comparison chart. Mild non-allergic asthma group (ANA) compared to mild allergic asthma group (AA)
[1096]
[1097]
[1098]
[1099] All values with AU C criteria> 0.75, good, very good or excellent are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; IL10 and POSTN (Periostin), IL8 and PI3; IL8 and POSTN.
[1100] 4. Comparisons between allergic asthmatics (AA) and non-asthmatic allergy sufferers (A) a. NO: Allergic asthmatics
[1101] b. N1: Non-asthmatic allergy sufferers.
[1102] c. AUC: Area Under the ROC Curve
[1103]
[1104] ROC curves
[1105] Variable N0 N1 AUC (95% CI) Threshold
[1106] CHI3L1 30 14 0.60 (0.36 - 0.84) 15719
[1107] IL10 21 4
[1108] IL8 14 7 0.88 (0.72 - 1.00) 67
[1109] PI3 30 14 0.63 (0.43 - 0.84) 7348
[1110] Periostin 30 14 0.80 (0.67 - 0.93) 14418
[1111] Upper msr1
[1112] Lower MSR1
[1113] PHLDA1 6 7 0.48 (0.12 - 0.83) 0.025
[1114] SERPINB2 11 5 0.93 (0.80 - 1.00) 0.116
[1115]
[1116] ROC curves for models with combinations of two variables
[1117] Variables Variables Combination N0 N1 qualitative quantitative CHI3L1 + IL8 14 7 0.91 (0.78 - 1.00) 0.95 (0.87 - 1.00) CHI3L1 + PI3 30 14 0.58 (0.35 - 0.80) 0.83 (0.70 - 0.96) CHI3L1 + Periostin 30 14 0.81 (0.68 - 0.94) 0.91 (0.84 - 0.97) CHI3L1 + PHLDA1 6 7 0.43 (0.09 - 0.77) 0.68 (0.40 - 0.96) CHI3L1 + SERPINB2 11 5 1.00 (1.00 - 1.00) 0.96 (0.90 - 1.00) IL8 + PI3 14 7 0.89 (0.75 - 1.00) 0.89 (0.76 - 1.00) IL8 + Periostin 14 7 0.90 (0.75 - 1.00) 0.94 (0.85 - 1.00) PI3 + Periostin 30 14 0.80 (0.66 - 0.93) 0.90 (0.81 - 0.98) PI3 + PHLDA1 6 7 0.76 ( 0.48 - 1.00) 0.77 (0.51 - 1.00) PI3 + SERPINB2 11 5 0.96 (0.88 - 1.00) 0.98 (0.94 - 1.00) ROC curves for models with combinations of three variables
[1118] Variables Variables
[1119] Variable N0 N1 qualitative quantitative
[1120]
[1121] CHI3L1 PI3 Periostin 30 14 0.80 (0.67 - 0.93) 0.95 (0.89 - 1.00)
[1122]
[1123] IL8 PI3 Periostin 14 7 0.93 (0.82 - 1.00) 0.94 (0.83 - 1.00)
[1124]
[1125] Comparison chart. Asthmatic group asthmatic allergic (AA) and allergic (A) non-asthmatic
[1126]
[1127]
[1128]
[1129] All values with AU C criteria> 0.75, good, very good or excellent are indicated. Of these, an improvement or synergy is observed between: CHI3L1 and IL8; CHI3L1 and SERPINB2; PI3 and PHLDA1; PI3 and SERPINB2; minimum between CHI3L1 and POSTN; minimum between IL8 and PI3 and IL8 and POSTN.
[1130] 5. Comparisons between severe allergic asthma (AA) and non-asthmatic allergic (A)
[1131] to. NO: Severe allergic asthmatics
[1132] b. N1: Non-asthmatic allergy sufferers
[1133]
[1134] ROC curves
[1135] Variable N0 N1 AUC (95% CI) Threshold
[1136] CHI3L1 15 14 0.60 (0.36 - 0.84) 15719
[1137] IL10 13 4
[1138] IL8 7 7 0.80 (0.55 - 1.00) 1023
[1139] PI3 15 14 0.66 (0.44 - 0.88) 7348
[1140] Periostin 15 14 0.77 (0.58 - 0.95) 14732
[1141] Upper msr1
[1142] Lower MSR1
[1143] PHLDA1 3 7
[1144] SERPINB2 6 5
[1145]
[1146] ROC curves for models with combinations of two variables
[1147] Variables Variables Combination N0 N1 quantitative qualitative CHI3L1 + IL8 7 7 0.82 (0.58 - 1.00) 0.90 (0.73 - 1.00) CHI3L1 + PI3 15 14 0.62 (0.40 - 0.84) 0.83 (0.68 - 0.97) CHI3L1 + Periostin 15 14 0.78 (0.61 - 0.96) 0.90 (0.82 - 0.98) IL8 + PI3 7 7 0.82 (0.58 - 1.00) 0.93 (0.79 - 1.00) IL8 + Periostin 7 7 0.90 (0.73 - 1.00) 0.91 (0.79 - 1.00) PI3 + Periostin 15 14 0.80 (0.62 - 0.97) 0.91 (0.81 - 1.00) ROC curves for models with combinations of three variables
[1148] Variables Variables
[1149] Variable N0 N1 qualitative quantitative
[1150]
[1151] CHI3L1 PI3 Periostin 15 14 0.80 (0.63 - 0.98) 0.95 (0.89 - 1.00)
[1152] IL8 PI3 Periostin 7 7 0.98 (0.92 - 1.00) 0.97 (0.90 - 1.00)
[1153]
[1154] Comparison chart. Asthmatic group severe allergic asthma (AA) and non-asthmatic allergic (A)
[1155]
[1156]
[1157]
[1158] All values with AU C criteria> 0.75, good, very good or excellent are indicated. Of these, an improvement or synergy is observed between: IL8 and POSTN; Minimum between CHI3L1 and IL8; CHI3L1 and POSTN; IL8 and PI3; PI3 and POSTN.
[1159] 6. Comparisons between mild allergic asthma (AA) and non-asthmatic allergic (A)
[1160] to. NO: Mild allergic asthmatics.
[1161] b. N1: Non-asthmatic allergy sufferers.
[1162] c. AUC: Area Under the ROC Curve
[1163] ROC curves
[1164] Variable N0 N1 AUC (95% CI) Threshold
[1165] CHI3L1 15 14 0.60 (0.35 - 0.84) 16093
[1166] IL10 8 4
[1167] IL8 7 7 0.96 (0.86 - 1.00) 67
[1168] PI3 15 14 0.60 (0.38 - 0.83) 7256
[1169] Periostin 15 14 0.83 (0.67 - 1.00) 14418
[1170] Upper msr1
[1171] Lower MSR1
[1172] PHLDA1 3 7
[1173] SERPINB2 5 5 0.84 (0.57 - 1.00) 0.116
[1174]
[1175] ROC curves for models with combinations of two variables
[1176] Variables Variables Combination N0 N1 quantitative qualitative CHI3L1 + PI3 15 14 0.57 (0.33 -0.81) 0.83 (0.69 - 0.97) CHI3L1 + Periostina 15 14 0.82 (0.66 - 0.99) 0.92 (0.84 - 0.99) IL8 + PI3 7 7 0.96 (0.86 - 1.00) 0.96 (0.87 - 1.00) IL8 + Periostin 7 7 0.94 (0.82 - 1.00) 0.94 (0.82 - 1.00) PI3 + Periostin 15 14 0.80 (0.63 - 0.98) 0.89 (0.77 - 1.00) PI3 + SERPINB2 5 5 0.92 (0.74 - 1.00) 0.96 (0.87 - 1.00) ROC curves for models with combinations of three variables
[1177] Variables Variables Variable N0 N1 qualitative quantitative CHI3L1 PI3 Periostina 15 14 0.81 (0.64 - 0.98) 0.94 (0.87 - 1.00) IL8 PI3 Periostina 7 7 0.96 (0.86 - 1.00) 0.97 (0.90 - 1.00)
[1178]
[1179] Comparison chart. Asthmatic group mild allergic (AA) asthmatic and non-asthmatic allergic (A)
[1180]
[1181]
[1182]
[1183] All values with AU C criteria> 0.75, good, very good or excellent are indicated. Of these, only an improvement or synergy is observed between: PI3 and SERPINB2.
[1184] Protein expression comparisons between clinical phenotypes. AUC values of the analysis of ROC curves by combination of the protein expression of three biomarkers.
[1185]
[1186] A) Non-allergic asthmatic group (ANA) compared to the asthmatic allergic group (AA).
[1187]
[1188]
[1189]
[1190]
[1191] In bold are the AUC values> 0.75, whose biomarker combinations give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed in: 1. Total ANA group compared to AA between: CHI3L1 IL10 POSTN; CHI3L1 IL8 PI3; CHI3L1 IL8 POSTN; CHI3L1 PI3 POSTN; CHI3L1 PI3 SERPINB2; CHI3L1 POSTN SERPINB2; IL10 IL8 + PI3; IL10 IL8 + POSTN; IL10 PI3 POSTN; IL8 PI3 POSTN; IL8 PI3 SERPINB2; IL8 POSTN + SERPINB2; PI3 POSTN SERPINB2; PI3 PHLDA1 + SERPINB2; Minimally between CHI3L1 POSTN PHLDA1, CHI3L1 IL10 IL8. 2. In the moderate / mild ANA group compared to the AA M / L group between: CHI3L1 IL10 POSTN; CHI3L1 PI3 POSTN; IL10 + PI3 + POSTN; IL8 + PI3 + POSTN. 3. In the severe ANA group compared to severe AA between: CHI3L1 IL8 PI3; CHI3L1 IL8 POSTN; CHI3L1 PI3 POSTN; IL10 + PI3 + POSTN; IL8 + PI3 POSTN. Total: total group of subjects in the group. ML: group of subjects with moderate-mild asthma. G: group of subjects with severe asthma
[1192]
[1193] B) Asthmatic allergic group (AA) compared to the non-asthmatic allergic group (A).
[1194]
[1195]
[1196]
[1197]
[1198] In bold are the AUC values> 0.75, whose biomarker combinations give rise to a good, very good or excellent category test. Of these, an improvement or synergy is observed in: 1. Total AA group compared to A among: CHI3L1 IL8 PI3; IL8 PI3 POSTN. 2. In group moderate / mild AA compared to group A between: CHI3L1 PI3 POSTN; IL8 + PI3 + POSTN. 3. In severe AA group compared to A: CHI3L1 IL8 PI3; CHI3L1 PI3 POSTN; IL8 + PI3 POSTN. Total: total group of subjects in the group. ML: group of subjects with moderate-mild asthma. G: group of subjects with severe asthma.
[1199] Global assessment of results of protein biomarkers to discriminate between clinical phenotypes.
[1200]
[1201] Based on the analysis of individual and grouped ROC curves of the 8 protein biomarkers studied, the best options for biomarkers for each clinical condition analyzed would be those detailed below.
[1202]
[1203] 1. Biomarkers capable of discriminating ANA (Non-allergic asthmatics) from Allergic Asthmatics (AA)
[1204] AUC CHI3L1 0.74
[1205] IL10 + Periostin 0.87
[1206] CHI3L1 + SERPINB2 0.83
[1207] CHI3L1 + IL8 0.82
[1208] IL8 + SERPINB2 0.82
[1209] PHLDA1 + SERPINB2 0.80
[1210] IL8 + Periostin 0.76
[1211] CHI3L1 + IL10 + Periostin 0.92
[1212] CHI3L1 + IL8 + Periostin 0.88
[1213] PI3 + PHLDA1 + SERPINB2 0.84
[1214] CHI3L1 + PI3 + Periostin 0.80
[1215]
[1216] 2. Biomarkers capable of discriminating severe ANA (Non-allergic Asthmatics) from severe Allergic Asthmatics (AA).
[1217]
[1218] AUC CHI3L1 0.82
[1219] SERPINB2 0.78
[1220] IL10 + Periostin 0.94
[1221] PI3 + SERPINB2 0.92
[1222] CHI3L1 + IL8 0.86
[1223] CHI3L1 + Periostin 0.86
[1224] IL8 + Periostin 0.86
[1225] CHI3L1 + IL8 + Periostin 0.96
[1226] 3. Biomarkers capable of discriminating Mod / mild ANA (Non-allergic Asthmatics) from Mod / mild Asthmatics (AA).
[1227] AUC CHI3L1 + IL8 0.86
[1228] IL10 + Periostin 0.82
[1229] IL8 + PI3 0.82
[1230] IL8 + Periostin 0.82
[1231] CHI3L1 + IL10 + Periostin 0.90
[1232] CHI3L1 + PI3 + Periostin 0.80
[1233]
[1234] 4. Biomarkers capable of discriminating AA (Allergic Asthmatics) from Allergic (A).
[1235] AUC IL8 0.88
[1236] Periostin 0.8
[1237] SERPINB2 0.93
[1238] CHI3L1 + SERPINB2 1
[1239] PI3 + SERPINB2 0.96
[1240] CHI3L1 + IL8 0.91
[1241] CHI3L1 + Periostin 0.81
[1242] IL8 + PI3 + Periostin 0.93
[1243]
[1244] 5. Biomarkers capable of discriminating severe AA (Allergic Asthmatics) from Allergic (A).
[1245] AUC IL8 0.80
[1246] Periostin 0.77
[1247]
[1248] IL8 + Periostin 0.90
[1249] IL8 + PI3 + Periostin 0.98
[1250] 6. Biomarkers able to discriminate Mod / mild AA (Allergic Asthmatics) from Allergic (A).
[1251] AUC IL8 0.96
[1252] Periostin 0.83
[1253] SERPINB2 0.84
[1254] PI3 + SERPINB2 0.92

权利要求:
Claims (7)
[1]
1. In vitro method for diagnosing subjects with allergic asthma, distinguishing the severity of allergic asthma from intermittent or persistent mild / moderate allergic asthma to that of severe allergic asthma, comprising: (a) measuring the concentration, in relative units, of at least the SERPINB2 protein by western blot, obtained from a biological sample isolated from blood, serum or plasma, of the subjects to be selected; and (b) comparing said concentration of at least the SERPINB2 protein of the selected subjects with an established pattern or level of expression based on the comparison between mild / moderate intermittent or persistent allergy sufferers of severe allergic asthmatics with a higher AUC. to 0.76, where the concentration level with respect to said established pattern or expression level of at least the SERPINB2 protein distinguishes the sub-phenotype of mild / moderate intermittent or persistent allergic asthma from that of severe allergic asthma.
[2]
2. In vitro method according to claim 1, wherein said method comprises: (a) measuring the pattern or level of expression of at least the SERPINB2 protein by western blot and PI3, periostin or CHI3L1, in pg / ml, obtained at from a biological sample isolated from blood, serum or plasma, of the subjects to be selected; and (b) comparing said pattern or level of expression of at least the SERPINB2 and PI3 protein, periostin or CHI3L1, of the subjects to be selected with a pattern or level of expression already established based on the comparison between mild intermittent or persistent allergy sufferers. / Moderate levels of severe allergic asthmatics with an AUC higher than 0.76, where the concentration level with respect to said pattern or established expression level of at least the SERPINB2 and PI3 protein, periostin or CHI3L1, distinguishes the sub-phenotype of intermittent allergic asthma or Mild / moderate persistent severe allergic asthma.
[3]
3. In vitro method for the diagnosis / prognosis of a subject suspected of having asthma, comprising steps a) and b) of any of the methods of claims 1 to 2, and optionally (c) confirming the presence of a certain phenotype of asthma and / or the severity of the disease through a clinical examination.
[4]
4. Method for obtaining useful data for the in vitro diagnosis / prognosis of asthma, comprising steps a) and b) of any of the methods of claims 1 to 2.
[5]
5. In vitro method for monitoring the response to therapy or for monitoring the progression of asthma, in a subject suffering from said disease, comprising steps a) and b) of any of the methods of claims 1 to 2.
[6]
6. Method according to any of claims 1 to 5, wherein the subject is a human subject.
[7]
7. Use of a kit comprising antibodies capable of detecting the level of differential expression of at least the SERPINB2 protein through the formation of immunoprecipitates alone or combined with diffusion and / or electrophoresis (Western-blot), in a biological blood sample, serum or plasma, to carry out the method of any of claims 1 to 2.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Trivedi et al.2019|Asthma in children and adults—what are the differences and what can they tell us about asthma?

---

Kuruvilla et al.2019|Understanding asthma phenotypes, endotypes, and mechanisms of disease

---

Sapey et al.2009|Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD

---

Kessel et al.2013|Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers

---

Xiangyang et al.2012|Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis

---

Larose et al.2015|Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: Involvement in patients with severe eosinophilic asthma

---

Karadag et al.2008|Biomarkers of systemic inflammation in stable and exacerbation phases of COPD

---

Csontos et al.2010|Time course of pro-and anti-inflammatory cytokine levels in patients with burns—prognostic value of interleukin-10

---

Pavlovic et al.2014|Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis

---

LIU et al.2009|Correlation between serum biomarkers and BODE index in patients with stable COPD

---

Zhu et al.2012|Serum inter-cellular adhesion molecule 1 is an early marker of diagnosis and prediction of severe acute pancreatitis

---

Park et al.2015|Interleukin-6 is associated with obesity, central fat distribution, and disease severity in patients with acute pancreatitis

---

Sperry et al.2014|X-Chromosome Linked IRAK-1 Polymorphism Is A Strong Predictor Of Multiple Organ Failure And Mortality Post-Injury

---

Lai et al.2015|YKL-40 is correlated with FEV1 and the asthma control test | in asthmatic patients: influence of treatment

---

ES2510390T3|2014-10-21|COPD diagnosis

---

Villalba et al.2020|Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients

---

Majster et al.2019|Salivary calprotectin is elevated in patients with active inflammatory bowel disease

---

Tuzcu et al.2019|Thiol/Disulfide homeostasis in patients with rheumatoid arthritis

---

Morozov et al.2016|Urinary cytokines as markers of latent inflammation in children with chronic pyelonephritis and anorectal malformations

---

ES2826385T3|2021-05-18|IL-10 as a prognostic biomarker of sensitivity to immunotherapy with house dust mite allergens

---

Lauer et al.2014|The advance of personalized and stratified therapies in bronchial asthma: phenotypes–endotypes–biomarkers

---

ES2697299B2|2020-04-15|DIFFERENTIAL BIOMARKERS OF ASTHMA

---

Sanhal et al.2016|Comparison of plasma fetuin A levels in patients with early-onset pre-eclampsia vs late-onset pre-eclampsia

---

Chen et al.2017|Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients

---

Almasood et al.2011|Human leukocyte antigen–G is upregulated in heart failure patients: A potential novel biomarker

同族专利:

---

公开号 | 公开日

---

ES2753602R1|2020-05-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

MX348362B|2008-03-31|2017-06-07|Genentech Inc |Compositions and methods for treating and diagnosing asthma.|

---

法律状态:
2020-04-13| BA2A| Patent application published|Ref document number: 2753602 Country of ref document: ES Kind code of ref document: A2 Effective date: 20200413 |

---

2020-05-20| EC2A| Search report published|Ref document number: 2753602 Country of ref document: ES Kind code of ref document: R1 Effective date: 20200512 |

---

2020-10-19| FA2A| Application withdrawn|Effective date: 20201013 |

优先权:

---

申请号 | 申请日 | 专利标题

---

ES202030118A|ES2753602R1|2017-07-19|2017-07-19|DIFFERENTIAL BIOMARKERS OF ASTHMA|ES202030118A| ES2753602R1|2017-07-19|2017-07-19|DIFFERENTIAL BIOMARKERS OF ASTHMA|